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Major	 depressive	 disorder	 (MDD)	 is	 a	 leading	 cause	 of	 disability	 worldwide	 and	 a	 major	
contributor	 to	 early	 mortality	 from	 suicide.	 It	 is	 a	 common	 psychiatric	 illness	 with	 a	 well-




Gene-environment	 interactions	 were	 tested	 in	 the	 Radiant	 UK	 recurrent	 depression	 sample	
using	polygenic	risk	scores	(PRS),	which	reflect	genetic	liability	for	MDD	based	on	many	common	










Genome-wide	 association	 studies	 on	 suicide	 attempt	 were	 conducted	 comparing	 6,569	
attempters	versus	17,232	non-attempters	from	MDD,	bipolar	disorder	and	schizophrenia	cases	
in	the	Psychiatric	Genomics	Consortium.	This	identified	three	genome-wide	significant	loci	for	
suicide	attempt	 in	mood	disorders,	which	will	be	 replicated	 in	 independent	 samples.	Finally,	
blood	mRNA	levels	of	SAT1,	PTEN,	MAP3K3	and	MARCKS	have	been	reported	as	biomarkers	for	
suicidality	 and	 here,	 an	 independent	 test	 in	 the	 Genome-Based	 Therapeutic	 Drugs	 for	






















































































Chapter	 3:	 The	 Radiant	 UK	 genotype	 data	 previously	 underwent	 quality	 control.	 The	meta-
analysis	of	PGC	major	depressive	disorder	cohorts	excluding	Radiant	UK	was	conducted	by	Dr.	







CNV	 calling.	 Polygenic	 risk	 scores	 were	 generated	 centrally	 by	 the	 statistics	 department	 at	
deCODE	genetics.	All	statistical	analyses	were	conducted	by	Niamh	Mullins	at	deCODE	genetics.	







quality	 control	 and	 imputation	 were	 performed	 centrally	 using	 the	 Psychiatric	 Genomics	
Consortium	 ‘Ricopili’	 pipeline.	All	 statistical	 analyses	were	 conducted	by	Niamh	Mullins.	 The	
paper	was	written	by	Niamh	Mullins	and	edited	with	feedback	from	Prof.	Cathryn	Lewis.		
	
Chapter	 6:	 Quality	 control	 on	 GENDEP	 gene	 expression	 data	 was	 performed	 by	 Dr.	 Karen	
















Major	 depressive	 disorder	 (MDD)	 is	 a	 common	 psychiatric	 illness	 and	 a	 global	 public	 health	
problem.	 It	 is	 the	 third	 leading	 cause	 of	 years	 lived	 with	 disability	 worldwide	 and	 a	 major	









four	 other	 symptoms	 which	may	 include	 weight	 and	 sleep	 changes,	 cognitive	 impairments,	
psychomotor	symptoms	and	suicidality	(American	Psychiatric	Association,	2013).	Table	1	shows	
the	 nine	 core	 symptoms	 of	MDD	 according	 to	 the	 current	 criteria	 from	 the	 Diagnostic	 and	
Statistical	Manual	of	Mental	Disorders	5th	edition	 (DSM-5)	 (American	Psychiatric	Association,	
2013).	 These	 symptoms	 should	 represent	 a	 change	 from	 previous	 functioning	 and	 not	 be	
attributable	to	the	effects	of	a	substance,	another	medical	condition	or	psychiatric	disorder.	The	


































Treatment	 options	 for	 MDD	 are	 mainly	 pharmacotherapy,	 psychological	 therapy	 or	 a	
combination	 of	 both	 (Otte	 et	 al.,	 2016).	Medication	 is	 typically	 prescribed	 for	 moderate	 to	
severe	depression	and	most	 classes	of	 antidepressant	drugs	 act	 to	 increase	 the	 signalling	of	
monoamine	neurotransmitters,	such	as	serotonin	and	noradrenaline.	While	antidepressants	are	
effective	 for	some	patients,	 they	have	only	modest	efficacy,	with	 improvement	 in	symptoms	
taking	several	weeks	and	potentially	adverse	side	effects	such	as	sleep	disturbances,	headaches	










2000).	 Meta-analysis	 of	 concordance	 rates	 for	 MDD	 between	 monozygotic	 versus	 dizygotic	













Genome-wide	 association	 studies	 (GWAS)	 test	 for	 differences	 in	 allele	 frequencies	 between	
disease	and	control	groups	at	millions	of	biallelic	single	nucleotide	polymorphisms	(SNPs)	across	

















Among	GWAS	of	psychiatric	disorders,	 schizophrenia	 is	 the	 flagship	disorder	having	amassed	
large	 sample	 sizes	 faster	 than	 other	 disorders	 and	 so	 far	 identifying	 the	most	 genome-wide	
significant	 associations.	 Early	 GWAS	 on	 schizophrenia	 had	 sample	 sizes	 of	 ~3,000	 cases	 and	
found	 only	 one	 SNP	 passing	 the	 genome-wide	 significance	 threshold	 (International	
Schizophrenia	Consortium	et	al.,	2009).	Increasing	the	sample	size	to	over	17,000	schizophrenia	
cases	 identified	 7	 genetic	 associations	 (Schizophrenia	 Psychiatric	 Genome-Wide	 Association	
Study	Consortium,	2011).	In	2014,	a	landmark	GWAS	of	over	36,000	cases	and	113,000	controls,	
robustly	linked	108	independent	loci	to	schizophrenia,	and	this	number	has	now	increased	to	















small	 effect	 sizes,	 which	 act	 cumulatively	 to	 increase	 risk.	 Simultaneously	 investigating	













proportion	of	variance	 in	phenotype	explained	by	 the	PRS	usually	 starts	 to	 increase	as	 the	P	
value	 threshold	 is	 relaxed	 and	more	 SNPs	 are	 added,	 consistent	with	 the	 presence	 of	 small	




the	 Psychiatric	 Genomics	 Consortium,	 2014).	 A	 PRS	 derived	 from	 a	 discovery	GWAS	 on	 one	









more	 true	 associations	 and	 estimate	 their	 effect	 sizes	with	 greater	 accuracy,	 the	 amount	 of	
variance	explained	by	polygenic	risk	scores	will	increase	(Dudbridge,	2013).	PRS	generated	from	
the	 latest	 schizophrenia	 GWAS	 results	 can	 now	 explain	 11%	 of	 phenotypic	 variance	 in	
schizophrenia	case-control	samples	(Pardiñas	et	al.,	2016).	Online	GWAS	summary	association	
statistics	for	both	psychiatric	and	physical	disorders	and	the	availability	of	software	tools	has	
enabled	 a	 range	 of	 informative	 research	 using	 polygenic	 risk	 scoring	 (Euesden	 et	 al.,	 2015,	

































Genome-wide	 association	 studies	 on	 MDD	 have	 lagged	 behind	 schizophrenia	 and	 other	
psychiatric	disorders.	In	2013,	in	a	mega-analysis	of	over	9,000	clinically	ascertained	MDD	cases	
and	 9,000	 healthy	 controls	 conducted	 by	 the	 PGC,	 no	 SNPs	 reached	 the	 genome-wide	
significance	 threshold	 (Major	 Depressive	 Disorder	 Working	 Group	 of	 the	 Psychiatric	 GWAS	
Consortium	 et	 al.,	 2013).	 Studies	 of	 this	 sample	 size	 on	 most	 other	 human	 diseases	 had	
produced	significant	results.	Several	characteristics	of	MDD	pose	challenges	to	genetic	analysis,	
for	 example	 its	 moderate	 heritability,	 high	 prevalence	 and	 the	 heterogeneity	 of	 depressive	

















Along	with	 the	main	effects	of	 genetics	 and	environment,	 gene-by-environment	 interactions	
(GxE)	whereby	genetic	effects	are	moderated	by	specific	environmental	factors,	may	also	play	a	
role	 in	 depression	 (Halldorsdottir	 and	 Binder,	 2017).	 Many	 individuals	 who	 are	 exposed	 to	
environmental	 stressors	 do	 not	 become	depressed	 and	 it	 has	 been	 suggested	 that	 this	may	
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with	 particular	 functions.	 Given	 the	 lack	 of	 success	 of	 candidate	 gene	 interaction	 studies,	





and	 controls	 with	 heterogeneous	 exposures	 and	 thus	 analysing	 SNP	 effects	 across	 average	
environmental	backgrounds.	Reducing	environmental	heterogeneity	could	be	a	useful	strategy	
to	 increase	 effect	 sizes	 and	 uncover	 more	 genetic	 associations,	 which	 are	 missed	 by	
conventional	GWAS.	Understanding	the	interplay	between	genes	and	environment	can	further	
elucidate	 the	 pathophysiology	 of	 depression	 and	 could	 potentially	 target	 treatment	 and	










A	key	 feature	of	 depression	 and	other	psychiatric	 disorders	 is	 that	 affected	 individuals	 have	
significantly	fewer	children	compared	with	the	general	population	(Power	et	al.,	2013a).	This	
along	with	the	substantial	heritability	and	prevalence	of	psychiatric	disorders	is	an	evolutionary	












populations	 (Schork	 et	 al.,	 2009).	 A	 recent	 paper	 reported	 that	 common	 schizophrenia	 risk	
alleles	can	persist	through	background	selection,	a	process	by	which	negative	selection	against	




population	 samples.	 Natural	 selection	 shapes	 the	 genetic	 landscape	 of	 heritable	 traits	 and	










worldwide	 public	 health	 problem	with	 over	 800,000	 deaths	 each	 year	 and	 suicide	 attempts	
occurring	up	to	20	times	more	frequently	(World	Health	Organization,	2014).	These	stark	figures	
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could	 explain	 why	 some	 patients	 make	 suicide	 attempts,	 while	 the	 majority	 of	 psychiatric	
patients	do	not.	Twin	heritability	estimates	of	suicidal	behaviour	are	30-55%,	although	one	study	
showed	that	after	adjusting	for	psychiatric	disorders	this	reduced	to	17%	(Voracek	and	Loibl,	
2007,	 Fu	 et	 al.,	 2002).	 Consistent	 with	 a	 diathesis-stress	 model,	 suicide	 attempt	 may	 be	
considered	 conditional	 on,	 but	 independent	 of	 psychiatric	 disorders.	 This	 epidemiological	
evidence	suggests	that	suicidality	could	be	usefully	considered	as	a	comorbidity	rather	than	an	
intrinsic	 component	of	 the	psychiatric	disorders	 themselves.	 Indeed,	 the	DSM-5	 lists	Suicidal	





attempters	 with	 mood	 disorders,	 to	 test	 for	 genetic	 variants	 contributing	 independently	 to	
suicide	attempt	 (Willour	et	 al.,	 2012,	 Schosser	et	 al.,	 2011,	Perlis	 et	 al.,	 2010,	Mullins	et	 al.,	
2014b).	 These	 studies	 have	 failed	 to	 identify	 any	 replicable	 genetic	 associations,	 and	 with	
sample	sizes	of	 less	than	1,200	cases,	this	 is	 likely	explained	by	a	lack	of	power	to	detect	the	
small	genetic	effects	typical	for	a	single	SNP.	Other	GWAS	have	focused	on	subjects	recruited	
specifically	on	 the	basis	of	 suicide	attempt,	 rather	 than	a	particular	psychiatric	disorder,	but	
again	have	not	found	any	genetic	associations	(Galfalvy	et	al.,	2015).	However,	a	PRS	for	suicide	
attempt	 generated	 from	 the	 results	 of	 one	 GWAS,	 showed	modest	 association	with	 suicide	
attempt	in	an	independent	sample,	providing	evidence	that	suicide	attempt	is	a	polygenic	trait	











2	 provides	 a	 detailed	 review	 of	 the	 challenges	 that	 have	 faced	 depression	 genetics	 and	 the	
successful	strategies	adopted	by	recent	GWAS	(Mullins	and	Lewis,	2017).		The	first	progress	has	
been	made	 in	 identifying	 genetic	 variants	 involved	 in	 depression	with	 studies	 amassing	 the	
critical	sample	size	necessary	to	reach	an	inflection	point,	beyond	which	the	number	of	genetic	
associations	is	expected	to	increase	linearly.	The	overwhelming	evidence	is	that	depression	is	a	
heterogeneous	 disorder	 in	 terms	 of	 symptoms,	 genetics	 and	 environmental	 risk	 factors,	 but	
leveraging	this	heterogeneity	can	make	rapid	inroads	into	understanding	its	complex	aetiology.	
In	 the	 first	 research	 paper	 (Chapter	 3),	 I	 investigate	 interactions	 between	PRS	 for	MDD	and	
childhood	 trauma	 or	 adult	 stressful	 life	 events,	 using	 data	 from	 the	 Radiant	 UK	 sample	 of	
recurrent	depression	cases	and	healthy	controls	(Mullins	et	al.,	2016).		
		
Unaffected	 individuals	 will	 also	 carry	 alleles	 that	 increase	 risk	 of	 psychiatric	 disorders	 and	
studying	genetic	variation	at	a	population	level	can	provide	insight	into	genetic	architecture.	In	
collaboration	 with	 deCODE	 genetics,	 Chapter	 4	 examines	 whether	 polygenic	 risk	 scores	 for	




In	 the	 last	 two	 chapters	 of	 the	 thesis,	 I	 investigate	 the	 genetics	 of	 suicidality,	 a	 serious	 and	
understudied	comorbidity	of	depression	and	other	psychiatric	disorders.	Chapter	5	presents	the	
largest	GWAS	on	 suicide	 attempt	 in	 over	 6,000	 attempters	 and	 17,000	non-attempters	with	
MDD,	bipolar	disorder	and	schizophrenia,	recruited	from	the	PGC.	This	is	the	first	consortium-
based	GWAS	on	suicide	attempt	and	makes	progress	in	recruiting	the	large	sample	sizes	needed	
for	 robust	 genetic	 studies	 on	 this	 phenotype.	 There	 is	 a	 pressing	 need	 for	 biomarkers,	








Increases	 in	 sample	 size	 have	 led	 to	 vast	 progress	 in	 depression	 genetics,	 however	 many	
questions	about	the	aetiological	heterogeneity	of	MDD	remain	unresolved.	This	thesis	attempts	
to	fill	some	of	the	gaps	in	our	knowledge	by	exploring	the	complex	interplay	between	genes	and	
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Abstract
Purpose of Review We will describe the success of recent
genome-wide association studies that identify genetic variants
associated with depression and outline the strategies used to
reduce heterogeneity and increase sample size.
Recent Findings The CONVERGE consortium identified two
genetic associations by focusing on a sample of Chinese wom-
en with recurrent severe depression. Three other loci have
been found in Europeans by combining cohorts with clinical
diagnosis and measures of depressive symptoms to increase
sample size. 23andMe identified 15 loci associated with de-
pression using self-report of clinical diagnosis in a study of
over 300,000 individuals.
Summary The first genetic associations with depression have
been identified, and this number is now expected to increase
linearly with sample size, as seen in other polygenic disorders.
These loci provide invaluable insights into the biology of de-
pression and exciting opportunities to develop new bio-
markers and therapeutic targets.
Keywords Depression . Genetics . Genome-wide association
study . Heterogeneity . Polygenic
Introduction
Major depressive disorder (MDD) is a common psychiatric
illness and global public health problem [1]. It is the third
leading cause of years lived with disability worldwide and a
major contributor to early mortality from suicide [2].
Alleviating the burden of this costly disease is an important
priority; however, limited understanding of the biological ba-
sis of depression has hindered the development of novel treat-
ments and interventions.
Depression is a complex disorder with a heritability of 37%
estimated from twin studies [3]. Despite robust evidence for a
genetic component, identifying the specific genetic variants
involved in the disorder has been a major challenge.
Genome-wide association studies (GWAS) test differences in
allele frequencies between disease and control groups at mil-
lions of common single nucleotide polymorphisms (SNPs)
across the genome. These differences may be functionally
relevant to the disease or may represent loci which are trans-
mitted in linkage disequilibrium with a causative polymor-
phism. Early GWAS studies of MDD were not promising,
despite having sample sizes similar to successful studies for
other common diseases and traits, including psychiatric disor-
ders. In a GWAS of over 9000 clinically ascertained MDD
cases and 9000 healthy controls conducted by the Psychiatric
Genomics Consortium (PGC), no SNPs reached the genome-
wide significance threshold [4]. The CHARGE (Cohorts for
Heart and Aging Research in Genomic Epidemiology)
Consortium conducted a GWAS of depressive symptoms in
This article is part of the Topical Collection on Genetic Disorders
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over 30,000 individuals which also failed to identify any ge-
netic associations [5].
Challenges of Depression Genetics
There are several reasons why identifying risk loci for MDD
has proven difficult. First, like most complex diseases, depres-
sion is a polygenic disorder arising from the combined effect
of many genetic variants with individually small effect sizes
[6]. Several sources provide evidence for the polygenic archi-
tecture of depression, despite a lack of genome-wide signifi-
cant loci. Polygenic risk scoring uses association statistics
from a discovery GWAS to weight the genotypes of individ-
uals in an independent test sample and sums these effects
across multiple SNPs into a polygenic risk score (PRS) [7].
Differences in PRS between cases and controls in the inde-
pendent sample show that the PRS is capturing genetic sus-
ceptibility that is predictive of disease status. PRS for MDD
generated from results of the PGC GWAS showed modest,
although significant prediction for depression in independent
samples (R2 = 0.6%, P < 10−6), consistent with the presence of
small genetic effects that the original GWAS was underpow-
ered to detect at genome-wide significance [4]. SNP heritabil-
ity (h2SNP) is the proportion of trait variance attributable to
common SNPs and reflects a greater overall genetic similarity
between cases than controls [8]. The h2SNP ofMDD in the PGC
GWAS was 0.21 (s.e. 0.021) [4, 9], again confirming the
polygenic etiology of MDD. Large sample sizes are essential
to detect small individual genetic effects, and pooling samples
within research consortia has been key to the success of
GWAS on many human traits.
The second characteristic of MDD which poses challenges
to genetic analysis is its high lifetime prevalence of ~15% [1].
For a common disorder, the mean difference in phenotypic
liability between case and control groups is smaller, for both
unscreened and screened controls, and thus power to detect
allele frequency differences between them is reduced. Power
calculations show that samples 2.4-fold larger are needed for
GWAS of MDD compared with schizophrenia (prevalence
1%), to identify a variant that explains the same proportion
of risk [10]. Third, the heritability of MDD is modest, at 37%,
compared with other psychiatric disorders, meaning that risk
alleles are likely to have smaller effect sizes [3, 11]. To ac-
count for this lower heritability, samples 4–5 times larger
would be required for MDD than schizophrenia to capture
an equal amount of genetic variance [10].
Finally, depression is a particularly heterogeneous disorder.
Some genetic heterogeneity is inherent to polygenicity; affect-
ed individuals may have different combinations of risk alleles
and unaffected individuals will also carry many of these var-
iants. But subphenotyping of the nine core symptoms ofMDD
indicates that almost 1500 symptom combinations can fulfill
the diagnostic criteria and that two patients with a diagnosis of
MDD may not have a single symptom in common [12].
Subtypes of depression such as recurrence or early-onset
may be more heritable [3, 13]. Another striking example of
heterogeneity is sex differences, with depression twice as
prevalent among women than men and twin studies indicating
that ~45% of the genetic liability to MDD is not shared be-
tween sexes [14–16]. Polygenic risk scoring methods also
enable us to look for genetic similarities across traits and sug-
gest that postpartum depression may be more genetically sim-
ilar to bipolar disorder, that typical depression shows more
pleiotropy with schizophrenia, and that atypical depression,
characterized by increased appetite and weight, additionally
shares genetic effects with BMI [17, 18]. These findings to-
gether provide compelling evidence that depression is likely
composed of subtypes with differences in biological etiology
and a heterogeneous genetic architecture. Therefore, the suc-
cessful identification of genetic associations with MDD re-
quires either increased sample sizes or empirically driven ef-
forts to reduce heterogeneity. This review will outline recent
genetic studies on depression which have adopted such strat-
egies. Studies are described in detail, showing how each has
advanced our understanding of the genetic underpinnings of
depression, with summary information presented in Table 1.
CONVERGE Consortium
The CONVERGE (China , Oxford and Vi rg in ia
Commonwealth University Experimental Research on
Genetic Epidemiology) Consortium has collected a large de-
pression cohort with detailed clinical, genetic and environ-
mental data that is a powerful resource to dissect the etiology
of depression [19, 20•]. The study aimed to ascertain a more
homogeneous sample by restricting the phenotype to recurrent
severe depression in women. Using low-coverage sequencing
of 5303 Han Chinese MDD cases and 5337 controls screened
to exclude MDD, two SNPs on chromosome 10 showed evi-
dence of association: one near the SIRT1 gene and the other in
an intron of LHPP [20•]. Both loci replicated in an indepen-
dent Chinese sample and the genetic signal at the SIRT1 locus
increased when further restricting the sample tomelancholia, a
more severe subtype of MDD [20•]. This study demonstrates
the value of focusing on a homogeneous phenotype where
genetic effects should be larger and easier to detect, even at
the expense of a smaller sample size. SIRT1 is involved in the
biogenesis of mitochondria, which are the cell’s energy-
producing organelles. Supporting the genetic association, the
CONVERGE consortium report increased mitochondrial
DNA in MDD cases versus controls, with the amount of in-
crease positively correlated with stressors such as childhood
sexual abuse and lifetime adverse events [21].











Although these genetic associations are a considerable step
forward, the variants identified in individuals of East Asian
ancestry have low frequencies in populations of European
ancestry, and therefore no replication in the PGC depression
samples or other studies has been achieved [20•, 22•]. The
trans-ancestry genetic correlation between the PGC and
CONVERGE GWAS results is ~0.3, indicating there are like-
ly population differences in the genetic etiology of MDD, a
finding with important implications for future studies [23].
Further comparison of the studies using genetic correlation
and polygenic risk scoring weakly supports an overlap of
SNP effects between the studies and strengthens when focus-
ing on female only and recurrent MDD cases from the PGC
[23]. This indicates that some of the genetic differences be-
tween the PGC and CONVERGE results may be due to dif-
ferences in the specific MDD phenotype studied.
Social Science Genetic Association Consortium
The Social Science Genetic Association Consortium
(SSGAC) has pursued the alternate strategy of increasing
sample size, by analyzing multiple cohorts with heteroge-
neous measures of depression [24•]. They utilized data
from two case-control studies of MDD: summary statistics
from the PGC GWAS (9240 MDD cases, 9519 healthy
controls) and dbGaP-accessible genotypes from the
GERA (Resource for Genetic Epidemiology Research on
Adult Health and Aging) study (7231 MDD cases, 49,316
controls) [4, 25]. These clinical samples were meta-
analyzed with a GWAS on a measure of depressive symp-
toms in the UK Biobank, where adults in the general pop-
ulation were asked two questions about feelings of
unenthusiasm or disinterest and depression or hopelessness
in the past 2 weeks [26]. Combining these datasets resulted
in a sample of 180,866 individuals and found two genome-
wide significant associations with “depressive symptoms”
which replicated on look up in an independent depression
GWAS by 23andMe [24•]. One SNP is in the KSR2 (kinase
suppressor of ras 2) gene and the other is in the DCC gene,
which encodes a transmembrane receptor involved in axon
guidance. The h2SNP for depressive symptoms from the total
sample was 0.04 (s.e. 0.004), which is considerably lower
than the estimates from clinically ascertained MDD sam-
ples (~0.2 in both the PGC and CONVERGE studies) [9,
27]. This may result from mixing heterogeneous measures
of depression which are influenced by different combina-
tions of genetic variants and the weak information on de-
pression symptoms from just two questions. Nevertheless,
the SSGAC attributes the success of their study to
exploiting the genetic correlation between clinical depres-
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increase sample size [24•]. While such a strategy may in-
crease power for individual SNPs which influence both
clinical depression and depressive symptoms, it may dilute
associations for SNPs which only play a role in one phe-
notype and this has implications for replicating specific
associations in different samples.
23andMe
The direct-to-consumer genetic testing company 23andMe
(Mountain View, CA) also took the approach of increasing
sample size. They used self-report data from consumers who
participated in their research initiative and ascertained 75,607
individuals reporting previous clinical diagnosis or treatment
for major depression and 231,747 individuals reporting no
history of depression [22•]. They carried out meta-analysis
of these results with the PGCGWAS results and then analyzed
a replication sample of an additional 45,773 cases and
106,354 controls from 23andMe. A total of 17 independent
SNPs from 15 regions reached genome-wide significance af-
ter joint analysis over all three data sets (Table 1) [22•]. Two of
the loci were significant in both the meta-analysis and inde-
pendent replication sample. In a locus spanning MEF2C
(myocyte enhancer factor 2C) and TMEM161B (transmem-
brane protein 161B), two independent SNPs were significant.
MEF2C is a transcription factor which plays a role in synaptic
learning and memory and variants in the gene have been im-
plicated in epilepsy, mental retardation, and schizophrenia
[28–30]. The other locus encompasses the NEGR1 gene,
encoding neuronal growth regulator 1, which is involved in
neurite outgrowth [31].
The strategy of less intensive phenotyping used in this
study is a novel approach in psychiatric research, as cases
have traditionally been ascertained using structured clinical
interviews. To demonstrate the validity of the self-report mea-
sure, the authors calculated the genetic correlation between the
results from the 23andMe study and those from the PGC
GWAS. There was a high positive correlation of 0.72 (s.e.
0.09) between the results indicating common variant genetic
overlap [22•]. However the h2SNP from the meta-analysis of the
23andMe discovery cohort and the PGC GWAS was 0.06,
showing a substantially lower genetic component than the
PGC h2SNP estimate of 0.21 [9, 22•]. This indicates that while
the phenotypes are genetically correlated, the genetic signal in
the 23andMe sample is likely weaker than in the PGC, which
could reasonably be due to some diagnostic misclassification.
The success of this 23andMe study in identifying genetic var-
iants at genome-wide significance shows that large sample
size can outweigh any reduction in power from additional
heterogeneity or limited clinical information. Genotyping is
now inexpensive compared with conducting detailed clinical
interviews and 23andMe’s light-phenotyping approach may
be more likely to attract the large number of participants re-
quired in the absence of high-quality phenotype information.
CHARGE Consortium and PGC
Depression can be conceptualized along a spectrum of sever-
ity from subthreshold or minor depression toMDD of varying
severity (e.g., mild, moderate, severe). Using a continuum
approach to depression may augment statistical power be-
cause sample size can be increased substantially and individ-
uals who fall anywhere along the phenotypic spectrum can be
included. This was the rationale for combining the results of
the CHARGE consortium GWAS of depressive symptoms
and the PGC GWAS on MDD [32•]. Depressive symptoms
were evaluated in individuals over 40 years old using validat-
ed ques t ionnai res (most ly us ing the Center for
Epidemiological Studies Depression Scale CES-D), which fo-
cused on depressive symptoms in the previous weeks rather
than lifetime. This meta-analysis of a broad depression phe-
notype identified one genome-wide significant SNP, which
replicated in an independent sample comprising newly
ascertained MDD cases from the PGC and individuals
assessed for depressive symptoms from the Health and
Retirement Study [32•]. The SNP is located in an intron of
FHIT, which is expressed in several brain regions and encodes
a tumor suppressor protein also involved in oxidative stress
and the circadian clock [32•].
In this study, the genetic correlation (rg) between depres-
sive symptoms and MDD was 1.00 (s.e. 0.2) which supports
the concept of a depression continuum capturing similar ge-
netic underpinnings to a study of depression cases and con-
trols. Notably the h2SNP of the broad depression phenotype was
0.3 (s.e. 0.04), which was greater than the h2SNP of depressive
symptoms or MDD separately (0.04 (s.e. 0.01) and 0.21 (s.e.
0.02), respectively) [32•]. Testing the genetic correlation be-
tween different phenotypic measures before combining them
can be informative about heritability in the subsequent sample
and can be used to assess whether the sample size achieved
will be sufficient to outweigh any heterogeneity introduced.
Power and Study Design
The power of these studies to identify MDD-associated vari-
ants differs considerably by sample size and design. We cal-
culated the genotype relative risk (GRR) which the study had
50% power to identify (Table 1), assuming a multiplicative
model, allele frequency of 0.3, MDD prevalence of 15%, and
fully screened controls [33]. The power of 50% was chosen to
reflect the polygenic architecture of MDD, where many SNPs
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of modest effect sizes contribute, and each study has low
power to detect a specific variant, but higher power to detect
a subset of SNPs having a pre-specified GRR. Using standard
power calculations, the 23andMe study would have 50% pow-
er to detect a variant with GRR 1.024, but the PGC MDD
study could only detect a GRR of 1.11. However, such power
calculations make simplistic assumptions about study design,
for example that selected participants are divided into MDD
cases and controls (defined as non-cases), with cases generally
being over-sampled from the population. In practice, studies
such as CONVERGE and some PGC MDD cohorts select
severe, recurrent cases of MDD and exclude any individuals
with mild to moderate depression. This selection of severe
cases and healthier controls with no history of depression in-
creases the power of the study by inducing a larger difference
in allele frequency between cases and controls. In contrast,
study power will be reduced by any misclassification of cases
and controls, which may be more likely in studies based on
self-report or limited phenotypic information at a single time
point.
Two of the studies listed in Table 1 use a quantitative phe-
notype of the number of depressive symptoms (SSGAC,
CHARGE). The CHARGE study of 51,258 participants
would have 50% power to detect a variant accounting for
0.0058% of trait variance. A study of 180,000 participants,
similar to SSGAC, could detect a variant accounting for
0.017% of trait variance (with 50% power), but the SSGAC
study used only two questions on depressive symptoms, re-
ducing its power from this theoretical value.
The studies described here illustrate two approaches to dis-
sect the genetic contribution to depression: through a case-
control study of lifetime diagnosis of depression or using a
continuous measure of the count of depressive symptoms,
usually covering the previous 2 weeks. Although the time
scales for these measures differ, the genetic correlation be-
tween these measures is high, for example rg = 1 between
CHARGE and the PGC MDD study [32•]. The relationship
between the power of a case-control and continuous pheno-
type was derived by Yang et al. [34] and shows that a cohort
study with a continuous phenotype onN individuals has lower
power than a case-control study with N/2 cases and N/2 con-
trols when the disease prevalence is below 10%. This vali-
dates the design of studies such as CONVERGE, ascertaining
recurrent cases of MDD where the population prevalence in
China is already low at 3.6% [35]. InWestern countries where
MDD prevalence is 15–20%, studies based on an underlying
quantitative trait may have higher power than an equivalently
sized case-control study.
Studies must balance the trade-off between gains in power
from increased sample size or reduced heterogeneity. As the
results of CONVERGE and the 23andMe studies show, both
approaches can be successful in identifying genetic variants
for depression, and researchers need to decide which strategy
maximizes the use of their resources. Since depression is a
common disorder, large sample sizes can be accrued through
consortia and inventive new methods such as leveraging elec-
tronic medical records, population biobanks, and online re-
cruitment. One limitation of mixing heterogeneous measures
of depression or less intensive phenotyping is that any associ-
ations discovered may be more difficult to interpret. But the
approach of increasing sample size can be used to find loci
whose role in MDD can then be dissected in follow-up sam-
ples with more detailed phenotypic data, even if these have
smaller sample size. Large samples with different depression
phenotypes will help to disentangle the genetic background of
different forms of depression.
Environment
While the focus of this review is on genetics, the role of the
environment in depression cannot be ignored, with twin stud-
ies showing that it accounts for 63% of the variance [3]. In
contrast to genetic associations, the environmental risk factors
are well-established and include social isolation, unemploy-
ment, and relationship stressors [36]. Childhood abuse or ne-
glect is one of the strongest environmental risk factors, more
than doubling the risk for depression in adult life [37]. Gene-
by-environment interactions (G×E) whereby genetic effects
are moderated by specific environmental factors have long
been postulated to play a role in depression. Most G×E re-
search has focused on candidate genes such as the serotonin
transporter promoter polymorphism (5-HTTLPR) interacting
with stressful life events or childhood trauma. Over a decade’s
worth of studies on this interaction has produced inconsistent
results, and recently, an extensive, pre-registered meta-analy-
sis concluded a lack of evidence for the 5-HTTLPR interaction
with environmental adversity [38•].
Since the genetic liability for depression is known to be
polygenic, studies have begun to test for interactions between
environmental factors and polygenic risk scores, which capture
the cumulative effect of many common variants in a single
measure. To date, two studies have reported no interaction
between PRS for MDD and adult stressful life events in the
etiology of depression [39, 40]. Two studies have found sig-
nificant interactions between PRS for MDD and childhood
trauma, albeit in opposing directions [39, 41]. The reason for
these discrepant results is unclear but further research is war-
ranted as the detection of G×E has implications for future re-
search strategies to identify genetic associations. In the
Netherlands Study of Depression and Anxiety (NESDA),
PRS had a stronger effect on MDD in individuals exposed to
childhood trauma, which suggests that focusing on exposed
individuals could render genetic effects larger, more homoge-
neous and easier to detect [41]. However, in the RADIANT
UK study, the effect of PRS onMDD risk was stronger in those
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unexposed to childhood trauma, suggesting that more power
could be leveraged from GWAS by focusing only on individ-
uals not exposed to trauma, as these MDD cases may have a
stronger genetic predisposition. In summary, the analysis of
cohorts with heterogeneous environmental exposures may also
contribute to the difficulty in identifying genetic associations
with MDD. Thus far, SNPs have been analyzed across average
environmental backgrounds in GWAS but reducing environ-
mental heterogeneity could be a valuable strategy to increase
genetic effect sizes. There is a need for depression samples
with good quality environmental data, which now can be more
expensive and difficult to attain than genotype data.
Conclusions
The first progress has been made towards identifying genetic
variants involved in MDD with studies amassing the critical
sample size necessary to reach an inflection point beyond
which the number of genetic associations is expected to in-
crease linearly with sample size [42•]. The critical goal of
GWAS is to identify the biological pathways underpinning
depression and even risk alleles with small effects could yield
enormous insights. As sample sizes continue to increase,
MDD GWAS will uncover more and more of the genetic
architecture of this debilitating disorder, as we have seen in
GWAS studies on schizophrenia [30]. The next challenge is to
establish the molecular mechanisms by which GWAS loci
mediate their effects and translate these into much-needed
new biomarkers and therapeutic targets. We have turned the
corner in identifying genetic variants for depression, and the
next few years will bring exciting opportunities to turn bio-
logical findings into clinical tools.
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Background. Major depressive disorder (MDD) is a common and disabling condition with well-established heritability
and environmental risk factors. Gene–environment interaction studies in MDD have typically investigated candidate
genes, though the disorder is known to be highly polygenic. This study aims to test for interaction between polygenic
risk and stressful life events (SLEs) or childhood trauma (CT) in the aetiology of MDD.
Method. The RADIANT UK sample consists of 1605 MDD cases and 1064 controls with SLE data, and a subset of 240
cases and 272 controls with CT data. Polygenic risk scores (PRS) were constructed using results from a mega-analysis on
MDD by the Psychiatric Genomics Consortium. PRS and environmental factors were tested for association with case/con-
trol status and for interaction between them.
Results. PRS signiﬁcantly predicted depression, explaining 1.1% of variance in phenotype (p = 1.9 × 10−6). SLEs and CT
were also associated with MDD status (p = 2.19 × 10−4 and p = 5.12 × 10−20, respectively). No interactions were found be-
tween PRS and SLEs. Signiﬁcant PRSxCT interactions were found (p = 0.002), but showed an inverse association with
MDD status, as cases who experienced more severe CT tended to have a lower PRS than other cases or controls. This
relationship between PRS and CT was not observed in independent replication samples.
Conclusions. CT is a strong risk factor for MDD but may have greater effect in individuals with lower genetic liability
for the disorder. Including environmental risk along with genetics is important in studying the aetiology of MDD and
PRS provide a useful approach to investigating gene–environment interactions in complex traits.
Received 14 May 2015; Revised 22 September 2015; Accepted 22 September 2015; First published online 3 November 2015
Key words: Depression, genetics, gene–environment interactions, polygenic risk scoring.
Introduction
Major depressive disorder (MDD) is a global public
health problem and the second leading cause of
disability worldwide (Vos et al. 2012). The disorder
has a well-established genetic contribution, with a her-
itability of 37% (Sullivan et al. 2000). Genome-wide as-
sociation studies (GWAS) on depression have typically
failed to identify the speciﬁc genetic variants involved
(Ripke et al. 2013), although two loci have recently been
implicated in the CONVERGE study of Chinese
women with severe MDD (CONVERGE Consortium,
2015). Many environmental risk factors also increase
the risk of depression, including unemployment, social
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isolation and relationship stressors (Brown & Harris,
1978). Stressful life events (SLEs) can trigger new depres-
sive episodes and childhood trauma (CT) has been
shown to double the risk for depression in adulthood
(Kessler, 1997; Kendler et al. 1999; Nanni et al. 2012).
Gene–environment interactions (GxEs) whereby a
person inherits sensitivity to environmental factors
could also play an important role in MDD (Uher,
2014). GxEs have commonly been investigated using
single loci in candidate genes, for example the sero-
tonin transporter promoter polymorphism (5-HTTLPR)
and its interaction with SLEs in major depression
(Caspi et al. 2003). Despite this being the most widely
investigated GxE in psychiatry, numerous studies in-
cluding meta-analyses have produced discrepant
results (Risch et al. 2009; Karg et al. 2011; Uher, 2014).
There is more consistent evidence for an interaction be-
tween 5-HTTLPR and CT, conferring risk for persistent
depression in adulthood (Karg et al. 2011; Uher et al.
2011; Brown et al. 2013; Fisher et al. 2013).
Nevertheless, the conﬂicting results from GxE studies
in psychiatry have made these ﬁndings controversial
(Duncan & Keller, 2011).
Further analyses of the genetic effects on MDD have
indicated that the disorder is likely to be highly poly-
genic, arising from the combined effect of many risk
variants, each with small effect sizes (Wray et al.
2012; Ripke et al. 2013). Polygenic risk scoring can be
used to test the predictive power of multiple genetic
variants simultaneously. Subsets of single nucleotide
polymorphisms (SNPs) from a discovery GWAS are
selected according to their p value and weighted by
their effect size to create a polygenic risk score (PRS)
for each individual in an independent validation sam-
ple. The PRS can then be tested for its ability to differen-
tiate between case and control status in the validation
dataset (Purcell et al. 2009; Dudbridge, 2013). PRS
derived using results from the largest GWAS on MDD
by the Psychiatric Genomics Consortium have shown
signiﬁcant predictive ability for depression, explaining
about 0.9% of variance in case–control samples (Ripke
et al. 2013; Peyrot et al. 2014).
These ﬁndings have led to the hypothesis that GxEs
in a highly polygenic trait such as MDD may involve
multiple genetic variants rather than one speciﬁc
locus. Indeed, interactions between polygenic scores
for MDD and CT were found to increase risk for de-
pression in the Netherlands Study of Depression and
Anxiety (NESDA), accounting for 0.6% of variance in
MDD status (Peyrot et al. 2014). The dearth of signiﬁ-
cant results in GWAS of MDD may be partially due
to environmental inﬂuences not being accounted for
and investigation of GxEs could provide important
insights into the complex aetiology of the disorder.
Here we test for interactions between polygenic risk
for major depression and adult SLEs or CT in the
RADIANT UK study of recurrent MDD.
Method
Clinical sample collection
Depression cases (n = 1605) were drawn from three
studies previously described in the published litera-
ture. The RADIANT UK recurrent MDD sample is
comprised of the Depression Case Control (DeCC)
study and probands from the Depression Network
(DeNT) study of affected sibling pairs (Farmer et al.
2004; Cohen-Woods et al. 2009). UK-ascertained cases
from the Genome Based Therapeutic Drugs for
Depression (GENDEP) study were also included.
GENDEP is a prospective pharmacogenetic study of
patients with unipolar depression of at least moderate
severity, on a 12-week antidepressant treatment (Uher
et al. 2010). Brieﬂy, patients were diagnosed using the
Schedules for Clinical Assessment in Neuropsychiatry
Interview, according to standardized criteria (Wing
et al. 1990). Information was recorded on patients’
worst and second worst episodes of depression in the
DeCC and DeNT studies and on their current episode
in the GENDEP study (Lewis et al. 2010). Exclusion cri-
teria included personal or family history of other psy-
chiatric diagnoses besides anxiety disorder (Farmer
et al. 2004; Cohen-Woods et al. 2009; Uher et al. 2010).
Healthy controls (n = 1064) were available from the
DeCC study and the London site of the Bipolar
Affective Disorder Case–Control study (Gaysina et al.
2009; Lewis et al. 2010). Controls were screened for life-
time absence of all psychiatric disorders using the Past
History Schedule (McGufﬁn et al. 1986). First-degree
family history of any psychiatric disorder or a score
of 10 or more on the Beck Depression Inventory at
interview were further exclusion criteria (Beck et al.
1996; Cohen-Woods et al. 2009, 2010).
Replication analysis was conducted using recurrent
depression cases from The Genetics of Recurrent
Early-Onset Depression (GenRED) 1 study (n = 260),
the GenRED 2 study (n = 270) and the Depression
Genes and Networks (DGN) study (n = 469) (Shi et al.
2011; Battle et al. 2014). Individuals in all analyses
were of white European parentage and gave written
informed consent to participate. Further information
on clinical samples is provided in the online
Supplementary material.
Measures
Recurrent MDD was deﬁned according to standard cri-
teria, as having at least two episodes of moderate se-
verity, separated by two or more months of
remission (World Health Organization, 1993;
760 N. Mullins et al.
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American Psychiatric Association, 1994). Number of
episodes was not a requirement in the GENDEP
study, although the majority of cases were recurrent
(Lewis et al. 2010).
Whole-blood samples were collected in
ethylene-diamine-tetra-acetic acid (EDTA) from
depressed cases. DNA samples were collected from
controls by taking blood or using buccal mucosa
swabs returned via postal mail. DNA was extracted
and samples of sufﬁcient quantity and quality were
genotyped on the Illumina Human610-Quad
BeadChip (Illumina, Inc., USA) (Freeman et al. 2003;
Lewis et al. 2010).
Adult SLEs were assessed using the Brief Life Event
Questionnaire, which is a shortened version of the List
of Threatening Experiences Questionnaire (LTE-Q)
(Brugha et al. 1985). Childbirth was also included, giv-
ing a total of 12 items (Farmer et al. 2004) (online
Supplementary material). Cases in the DeCC and
DeNT studies were asked to report on whether or
not they experienced each SLE in the 6 months prior
to their worst episode of depression, while GENDEP
cases were asked to report on the 6 months preceding
the clinical trial (Keers et al. 2011; Fisher et al. 2012).
Controls reported on the 6 months prior to their inter-
view. The number of reported SLEs was summed for
each individual and analysed as a quantitative variable
with range 0–12. Following the LTE-Q categories, SLEs
were split into those considered dependent on an indi-
vidual’s behaviour and those which seem independent
(Brugha et al. 1985). Dependent SLEs included un-
employment, separation, ﬁnancial or legal difﬁculties
and the birth of a baby. Independent events included
personal illness, illness of a family member, death of
a family member and being robbed. This gave a total
of seven dependent and ﬁve independent SLEs (online
Supplementary material). Mood at the time of inter-
view was assessed using the self-report Beck
Depression Inventory in the DeCC and GENDEP
cases (Beck et al. 1996).
A subset of the sample (n = 240 cases, n = 272 con-
trols) completed the self-report Childhood Trauma
Questionnaire, which measures frequency and severity
of sexual, physical and emotional abuse, physical and
emotional neglect during childhood, using 25
Likert-type items (Bernstein et al. 2003). CT was
ﬁrstly analysed as a quantitative score with range 25–
125. To explore results, CT was divided into categories
of none, mild and moderate/severe, according to a
deﬁnition described previously in this sample (Fisher
et al. 2013). The GenRED and DGN replication studies
assessed CT with the self-report Childhood Events
Questionnaire (E. Nelson and D. Levinson, unpub-
lished observations), which is based on the US
National Comorbidity Survey CT screening items
(Kessler et al. 1997) and CT questionnaires from
Washington University (Nelson et al. 2002). These
items cover severity and frequency of sexual abuse,
physical abuse and trauma (within and outside the
family), and emotional neglect.
Quality control
Standard quality-control procedures were implemen-
ted to clean genetic data, leaving 471 747 SNPs
(Lewis et al. 2010). Principal components (PCs) were
calculated using EIGENSTRAT (Price et al. 2006). The
ﬁrst two PCs reduced the genomic control parameter
(γ) to 1.02, indicating little difference between
RADIANT UK cases and controls due to population
stratiﬁcation or other systematic genomic effects
(Lewis et al. 2010). Missing information on age at
worst episode of depression (233 cases) and age at
interview (34 controls) was replaced with the mean
age at worst episode or interview in males or females
as appropriate. Number of SLEs was signiﬁcantly asso-
ciated with age (p = 3.64 × 10−8) and sex (p = 0.001),
with younger individuals and females reporting more
SLEs. Since depressed cases were younger than con-
trols and contained a greater proportion of females,
the number of SLEs was adjusted in cases to remove
bias due to age and sex. Using controls as a proxy
for the general population, a linear regression of
SLEs on age and sex was used to estimate their associ-
ation. These regression coefﬁcients were then used to
adjust the number of SLEs in depressed cases.
Dependent and independent SLEs were adjusted sep-
arately in the same manner. CT score was not asso-
ciated with age or sex, so no adjustment was
performed.
Statistical analysis
Polygenic scores were constructed using summary
results available online from the Psychiatric
Genomics Consortium (https://pgc.unc.edu/) MDD
GWAS (Ripke et al. 2013). The RADIANT UK sample
was removed to provide an independent validation
dataset and a meta-analysis of the remaining eight
studies was conducted (7615 cases and 7931 controls).
These discovery GWAS results were pruned for link-
age disequilibrium (LD) using the p value informed
clumping method in PLINK v1.07 (http://pngu.mgh.
harvard.edu/purcell/plink/), based on the LD structure
from the RADIANT UK dataset (Purcell et al. 2007).
Clumping preferentially retains SNPs with the stron-
gest evidence of association and removes SNPs in
high LD (r2 > 0.25 within a 300 kb window, ﬁltering
for signiﬁcance, PLINK-command: --clump-p1 0.5
--clump-p2 0.1 --clump-r2 0.25 --clump-kb 300).
Subsets of SNPs were selected from the results at
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nine increasingly liberal p value thresholds (pT <
0.0001, pT < 0.001, pT < 0.01, pT < 0.05, pT < 0.1, pT < 0.2,
pT < 0.3, pT < 0.4, pT < 0.5). These sets of alleles,
weighted by their log odds ratios (ORs) from the dis-
covery study, were summarized into PRS for each indi-
vidual in the validation sample using PLINK (Purcell
et al. 2009). pT < 0.5 contained 87 737 SNPs.
PRS for MDD were tested for ability to predict case/
control status in RADIANT UK using logistic re-
gression in R (http://www.r-project.org) to calculate
the Nagelkerke’s pseudo-R2 measure of variance
explained, excluding the variance accounted for by
two PCs (Nagelkerke, 1991). SLEs and CT score were
also tested for association with case/control status.
Interactions between PRS and SLEs or CT were inves-
tigated using two models. A multiplicative model tests
interaction as departure from multiplicativity, meaning
that the combined effect of PRS and environment dif-
fers from the product of their individual effects. This
was tested using a logistic regression, co-varying for
the main effects of PRS, environment and two PCs.
Models were also adjusted for PC × environment and
PC × PRS interactions (Keller, 2014). The interaction
term was tested for its ability to differentiate between
case and control status in the validation sample by cal-
culating Nagelkerke’s pseudo-R2. An additive inter-
action model tests whether the combined effect of
PRS and environment differs from the sum of their in-
dividual effects. It has been suggested that this better
captures the biological mechanism of GxEs (Rothman
et al. 2008). Interaction as departure from additivity
was tested using linear regression of MDD case/control
status on the interaction term, with covariates as
described previously. The multiple-R2 measure of vari-
ance explained by the interaction was calculated. To in-
vestigate gene–environment correlations, whereby
genotypes may inﬂuence exposure to different envir-
onments, PRS for MDD were tested for association
with SLEs or CT score using a linear regression,
co-varying for two PCs. Empirical p values were calcu-
lated using permutation procedures for all analyses.
Ten independent tests were conducted, giving a
Bonferroni corrected signiﬁcance threshold of 0.005.
In the replication phase, gene–environment correla-
tions between PRS and CT score in depressed subjects
were tested in MDD cases from the independent
GenRED and DGN samples.
Power calculations for our study were performed in
QUANTO version 1.2.4 (Gauderman & Morrison,
2009), using ORs reported in the literature for the
effects of PRS (OR = 1.22), 2+ SLEs (OR = 1.82) and CT
(OR = 2.27) on MDD (Nanni et al. 2012; Motrico et al.
2013; Peyrot et al. 2014). The study had >80% power
to detect an interaction between PRS and SLEs with
an OR of 1.28 (at α = 0.05). In the subset with CT
data, there was >80% power to detect an interaction be-
tween PRS and CT with an OR of 1.76 (at α = 0.05).
Ethical standards
All procedures contributing to this work comply with
the ethical standards of the relevant national and institu-
tional committees on human experimentation and with
the Helsinki Declaration of 1975, as revised in 2008.
Results
Sample characteristics
Sample characteristics are shown in Table 1. Cases con-
tained a signiﬁcantly greater proportion of females
than controls and their mean age at worst episode of
depression was signiﬁcantly younger than mean age
at interview in controls. Cases had experienced signiﬁ-
cantly more SLEs and had higher CT scores than con-
trols (Table 1). In the subset of the sample with CT data
(240 cases and 272 controls), similar differences in sex
and age at interview were found between cases and
controls (p = 2.9 × 10−4 and p = 0.004, respectively).




(n = 1064) pa
Sex, n (%) 6.83 × 10−10
Male 471 (29.3) 436 (41.0)
Female 1134 (70.7) 628 (59.0)
Age, yearsb 36.7 (12.3) 41.5 (13.2) 4.16 × 10−19




Number of SLEsb 1.57 (1.48) 0.68 (0.87) 1.67 × 10−67
Number of
dependent SLEsb




0.69 (0.89) 0.44 (0.66) 1.29 × 10−11
Childhood trauma
scorec
46.31 (16.25) 32.75 (8.75) 7.13 × 10−26
Data are given as mean (standard deviation) unless other-
wise indicated.
SLEs, Stressful life events.
a p Values were calculated using a non-parametric Mann–
Whitney U test, with the exception of sex where a χ2 test
was used.
b For cases at worst episode of depression and for controls
at interview.
c Data were available on a subset of 240 cases and 272
controls. Statistics were calculated from individuals without
missing data.
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Interaction with SLEs
Polygenic scores derived from a meta-analysis of MDD
using data from the Psychiatric Genomics Consortium
showed signiﬁcant predictive ability for depression in
the RADIANT UK sample. As more SNPs were
added to the PRS at increasingly liberal p value thresh-
olds, the amount of variance explained increased. At
pT < 0.5, the polygenic score explained 1.1% of variance
in case/control status [p = 1.9 × 10−6, OR = 1.22, 95%
conﬁdence interval (CI) 1.12–1.32] (Fig. 1). After
adjustment for age and sex, total SLEs were still sign-
iﬁcantly associated with MDD status (p = 2.19 × 10−4),
explaining 0.7% of variance between cases and con-
trols. A greater number of dependent SLEs was asso-
ciated with case status and could predict 6.6% of
variance in phenotype (p = 1.35 × 10−25). Independent
SLEs showed signiﬁcant but weaker predictive ability
(p = 1.36 × 10−9, Nagelkerke’s pseudo-R2 = 0.019) and in
contrast to dependent SLEs, more independent events
were found in controls v. cases, after correction for
age and sex. Under a multiplicative model, there was
no interaction between the PRS and total number of
SLEs (Fig. 1). The largest R2 was 0.001 at pT < 0.001
(p = 0.12, OR = 1.05, 95% CI 0.98–1.12). Interactions be-
tween PRS and dependent or independent SLEs were
also non-signiﬁcant (Fig. 1). No interactions were
found under additive models (online Supplementary
material).
Interaction with CT
In the subset of the sample with CT data, the PRS did
not show signiﬁcant predictive ability for MDD (p =
0.078, Nagelkerke’s pseudo-R2 = 0.007, pT < 0.4), though
effects were in the expected direction (OR = 1.18, 95%
Fig. 1. Polygenic risk scores (PRS) for major depressive disorder and multiplicative interactions with stressful life events
(SLEs) used to predict depression in the RADIANT UK sample. The y-axis indicates Nagelkerke’s pseudo-R2, a measure of
the variance explained. On the x-axis the nine p value thresholds used to select single nucleotide polymorphisms in the
discovery phase are plotted left to right. depSLEs, Dependent SLEs; indepSLEs, independent SLEs; pT, p value threshold. * p <
0.005. For a colour ﬁgure, see the online version.
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CI 0.98–1.42) (Fig. 2). A higher CT score was signiﬁ-
cantly associated with depression status, explaining
30.2% of variance (p = 5.12 × 10−20). Multiplicative
interactions were found between polygenic scores for
MDD and CT (Fig. 2). The interaction at pT < 0.05
explained 1.9% of variance in the phenotype and was
signiﬁcant after multiple testing correction (p = 0.002).
There was an inverse association between the inter-
action and MDD status (OR = 0.96, 95% CI 0.94–0.98).
To visualize these results, interactions were plotted be-
tween categories of CT (none, mild, moderate/severe)
and PRS standardized to mean 0 and S.D. 1. Plotting
log odds of depression by polygenic score for each
CT category at the p value threshold with most signiﬁ-
cant interaction (pT < 0.05; p = 0.002) allows visualiza-
tion of the results (Fig. 3). For individuals who had
not experienced CT, a higher PRS for MDD was asso-
ciated with a higher risk of the disorder (Fig. 3; black
line). Individuals in the mild CT category were at an
increased risk of depression but this appeared to act in-
dependently of their genetic liability (mid-grey line).
Those who had experienced moderate/severe CT
were mostly depressed cases but interestingly the indi-
viduals at highest risk in this category had a lower PRS
than average (Fig. 3; light grey line). There were no
interactions between PRS and CT under additive mod-
els (online Supplementary material).
Gene–environment correlations
Gene–environment correlations were explored be-
tween PRS for MDD and number of SLEs. Signiﬁcant
correlations were found within the MDD cases, speciﬁ-
cally with dependent (pT < 0.001; p = 0.002) and not in-
dependent SLEs (online Supplementary material). No
signiﬁcant corrections were found between polygenic
score and CT score in the RADIANT UK sample (on-
line Supplementary material). As the interaction
Fig. 2. Polygenic risk scores (PRS) for major depressive disorder and multiplicative interaction with childhood trauma (CT)
used to predict depression in the RADIANT UK sample. The y-axis indicates Nagelkerke’s pseudo-R2, a measure of the
variance explained. On the x-axis the nine p value thresholds used to select single nucleotide polymorphisms in the discovery
phase are plotted left to right. pT, p value threshold. * p < 0.005. For a colour ﬁgure, see the online version.
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between PRS and CT showed an inverse association
with MDD status, the relationship between PRS and
CT score was tested in the independent GenRED and
DGN depression cases. No signiﬁcant correlations be-
tween PRS and CT score were found.
Mood at interview
To investigate whether low mood at the time of inter-
view may result in a recall bias for negative events,
cases severely depressed at interview were removed in
a sensitivity analysis. Gene–environment correlations
between PRS and dependent SLEs in cases were no
longer signiﬁcant, excluding those who were severely
depressed at interview (online Supplementary mater-
ial). Interactions between PRS and CT score remained
signiﬁcant after severely depressed cases were excluded
(online Supplementary material).
Discussion
Polygenic scores derived from the Psychiatric Genomics
Consortium MDD mega-analysis predicted depression
in the RADIANT UK sample, explaining 1.1% of vari-
ance in case/control status. This modest ﬁgure is in
line with previous estimates from this mega-analysis
and conﬁrms the presence of associated variants that
Fig. 3. Multiplicative interaction between standardized polygenic risk score for major depressive disorder (MDD) based on pT
< 0.05 and categories of childhood trauma. Shaded circles are cases and open circles are controls. pT, p value threshold. For a
colour ﬁgure, see the online version.
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the original GWAS was underpowered to detect (Ripke
et al. 2013; Peyrot et al. 2014). SLEs were also signiﬁcant
predictors of case/control status. We hypothesized that
given the polygenicity of MDD, testing interactions be-
tween polygenic scores and environmental adversity
could be a more powerful approach than using single
genetic variants in a candidate gene. No interactions
were found between PRS for MDD and total, dependent
or independent SLEs, which is in agreement with previ-
ous ﬁndings by Musliner et al. (2015).
In the subset of the sample with CT data, the PRS
failed to show signiﬁcant predictive ability for depres-
sion which probably reﬂects the restricted sample size.
Consistent with previous reports, CT was a strong risk
factor for recurrent MDD in adulthood (Nanni et al.
2012). Signiﬁcant interactions were found between
PRS and CT; however, there was an inverse association
with depression status. This appeared to be driven by
individuals who had experienced moderate/severe CT,
as those at highest risk in this category tended to have
a lower PRS than other cases or controls (Fig. 3). One
possible explanation is that CT may be more important
in the development of MDD for individuals who have
a low genetic risk than for individuals who have a high
genetic risk. This would be consistent with the liability
threshold model for MDD, where a combined effect of
many genetic risk variants together with an environ-
mental contribution causes an individual to cross the
liability threshold and become affected. Alternatively,
the experience of CT may be such a strong risk factor
for depression that genetics has a negligible effect.
In contrast to our results, the NESDA study found a
signiﬁcant PRS x CT interaction, whereby higher PRS
and severe CT increased the risk for MDD (Peyrot et al.
2014). The conﬂicting results of these studies may be
due to differences in design – for example, NESDA is a
population-based study, includes single-episode, recur-
rent and chronic depression, used a different instrument
for assessing CT and had a larger sample size (1645
MDD cases, 340 controls). It has been reported that inter-
action between 5-HTTLPR and CT speciﬁcally increases
risk for chronic depression in adulthood (Brown et al.
2013). This suggests that GxEs may be more speciﬁc
than anticipated and subtle differences between our
study and NESDA could have contributed to the dis-
crepant results. Similarly, our SLE assessment was for
the 6 months prior to the worst episode of depression
in recurrent depression cases. Testing SLEs preceding
the initial onset of depression or in single-episode de-
pression may identify different components of the
gene–environment aetiology of MDD.
Evidence of gene–environment correlation was
found, as polygenic scores for MDD increased expos-
ure to (or reporting of) dependent SLEs in MDD
cases (online Supplementary material). This suggests
that depressed individuals may select themselves into
environmental adversity by creating stressful life
events due to their own behaviour, which is known
as active gene–environment correlation. SLEs or the
reporting of SLEs is heritable (Power et al. 2013) and
twin studies have shown pleiotropy between the gen-
etic contribution to SLEs and genetic liability to de-
pression (Kendler & Karkowski-Shuman, 1997;
Silberg et al. 1999).
There are several strengths of this study. SLEs were
adjusted for age and sex prior to the analyses. The
amount of variance explained by the SLEs decreased
dramatically after adjustment (online Supplementary
material), which demonstrates the importance of
accounting for age and sex. It has been suggested
that low mood at the time of interview may cause re-
call bias for negative events; however, we found no
evidence that this inﬂuenced our results, consistent
with two previous analyses in the RADIANT UK sam-
ple (Fisher et al. 2012, 2013).
A number of limitations also warrant noting. The
discovery GWAS by the Psychiatric Genomics
Consortium was underpowered to detect the likely ef-
fect sizes in MDD, which reduces the ability to separate
modest signals from noise and achieve accuracy in es-
timation of the PRS (Dudbridge, 2013; Ripke et al.
2013). The PRS used in these analyses consists of
SNPs selected from a study of their main effect on
MDD, which may not be the same genetic variants
that are involved in GxEs. This could explain the non-
standard shape of the PRS histograms for the interac-
tions, in contrast to the usual pattern where variance
explained increases across the p value thresholds
(Figs 1 and 2). Our study design relied on retrospective
self-reports of depression and environment, which
may be less accurate if the events occurred a long
time ago. However, the worst episode of depression
is arguably the most memorable, and retrospective
self-reports of depressive episodes agree well with hos-
pital records (McGufﬁn et al. 1986; Kendler et al. 1993).
The detection of GxEs has implications for future re-
search strategies. Analysis of cohorts with heteroge-
neous environmental exposures may partially explain
the lack of success in detecting genetic associations
with MDD. Our results suggest that more power
could be leveraged from GWAS by focusing only on
individuals not exposed to CT as this might identify
‘more genetic’ cases of MDD. However, results of the
NESDA study suggest that focusing on exposed indivi-
duals could render genetic effects larger, more homo-
geneous and easier to detect (Flint & Kendler, 2014;
Peyrot et al. 2014). Polygenic interactions in MDD re-
quire further investigation in larger, similarly well-
characterized samples and could provide important
insights into the complex aetiology of depression.
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Woods,	2009,	 Farmer,	2004).	 The	GENDEP	clinical	 trial	was	 conducted	across	nine	European	
centres	and	UK	ascertained	cases	were	included	in	these	analyses	(Uher,	2010).	Patients	were	
diagnosed	 using	 the	 Schedules	 for	 Clinical	 Assessment	 in	 Neuropsychiatry	 Interview	 (SCAN),	
according	to	standardised	criteria	in	the	International	Classification	of	Diseases	10th	edition	(ICD-
10)	or	Diagnostic	and	Statistical	Manual	4th	edition	(DSM-IV)	(American	Psychiatric	Association,	










Depressed	 cases	 from	 the	 GenRED	 1,	 GenRED	 2	 and	 DGN	 studies	 were	 used	 in	 replication	
analyses.	Cases	in	the	GenRED	studies	were	recruited	in	clinical	settings	and	through	media	and	




Study DeCC	(n=1232)	(%) DeNT	(n=294)	(%) GENDEP	(n=79)	(%) Total	(n=1605)	(%)
Male	(%) 375	(30.4) 69	(23.5) 27	(34.2) 471	(29.3)
Female	(%) 857	(69.6) 225	(76.5) 52	(65.8) 1134	(70.7)
Mean	age	at	interview	(years)	(s.d.) 46.7	(12.3) 45.6	(11.0) 44.7	(12.3) 46.4	(12.1)
Mean	age	at	worst	episode	(years)	(s.d.) 36.5	(12.2) 35.1	(11.6) - 36.2	(12.1)
Mean	age	onset	(years)	(s.d.) 23.2	(11.5) 22.4	(10.4) 24.1	(14.6) 23.1	(11.4)
Mean	number	of	episodes	(s.d.) 2.8	(2.8) 3.1	(2.0) 3.4	(4.6) 2.48	(0.68)
Proportion	with	recurrent	MDD 1232	(100) 294	(100) 62	(78.5) 1588	(98.9)
Study DeCC	(n=183)	(%) DeNT	(n=57)	(%) GENDEP	(n=0)	(%) Total	(n=240)	(%)
Male	(%) 50	(27.3) 13	(22.8) - 63	(26.2)
Female	(%) 133	(72.7) 44	(77.2) - 177	(73.5)
Mean	age	at	interview	(years)	(s.d.) 44.3	(13.0) 45.9	(10.7) - 44.7	(12.5)
Mean	age	at	worst	episode	(years)	(s.d.) 34.2	(12.3) 34.1	(11.8) - 34.2	(12.1)
Mean	age	onset	(years)	(s.d.) 21.6	(11.2) 19.7	(9.7) - 21.1	(10.8)
Mean	number	of	episodes	(s.d.) 2.9	(2.5) 3.4	(2.2) - 3.0	(2.8)
















469	recurrent	MDD	cases	 from	participants	 in	an	online	survey	panel	 that	 is	 recruited	on	an	





Structured	Clinical	 Interview	for	 the	Diagnostic	and	Statistical	Manual	of	Mental	Disorders	 IV	
(SCID)	 and	 those	 not	 meeting	 the	 initial	 eligibility	 criteria	 were	 excluded	 (First,	 2002).		
Participants	were	all	of	European	ancestry	and	were	genotyped	on	the	Illumina	HumanOmni1-
Quad	BeadChip	(Illumina,	Inc.,	San	Diego,	USA)	(Battle,	2014).	Childhood	trauma	was	assessed	




















and	 sex	 was	 used	 to	 estimate	 their	 association.	 These	 regression	 coefficients	 were	 used	 to	
calculate	the	adjusted	number	of	SLEs	in	the	cases.		Dependent	and	independent	SLEs	in	cases	
were	adjusted	separately	in	the	same	manner.		Prior	to	adjustment,	the	total	number	of	SLEs	







An	additive	model	 tests	 interaction	as	departure	 from	additivity	meaning	 that	 the	combined	
effect	of	PRS	and	environment	differs	from	the	sum	of	their	individual	effects.		This	was	tested	
using	a	linear	regression	of	MDD	case/	control	status	on	the	interaction	term,	covarying	for	the	
main	 effects	 of	 PRS	 and	 environment	 and	 two	 PCs.	 Models	 were	 also	 adjusted	 for	 PC	 x	































Gene-environment	 correlations	were	 tested	using	 a	 linear	 regression	of	 polygenic	 scores	 for	
MDD	on	total	number	of	SLEs,	with	two	principal	components	as	covariates.	This	was	tested	in	




PT OR	(95%	C.I.) P	value Multiple-R
2 OR	(95%	C.I.) P	value Multiple-R2 OR	(95%	C.I.) P	value Multiple-R2
0.0001 1.00	(0.99	-	1.01) 0.569 0.0001136 	0.99	(0.97	-	1.01) 0.607 0.0000975 1.00	(0.98	-	1.02) 0.547 0.0001316
0.001 1.01	(0.99	-	1.02) 0.155 0.0007494 1.01	(0.99	-	1.03) 0.312 0.0003607 0.99	(0.97	-	1.02) 0.988 0.0000001
0.01 1.00	(0.99	-	1.02) 0.410 0.0002527 1.00	(0.98	-	1.02) 0.755 0.0000371 1.00	(0.98	-	1.02) 0.714 0.0000477
0.05 0.99	(0.98	-	1.01) 0.743 0.0000387 1.00	(0.98	-	1.02) 0.803 0.0000221 0.99	(0.96	-	1.01) 0.506 0.0001622
0.1 1.00	(0.98	-	1.01) 0.716 0.0000507 1.00	(0.98	-	1.02) 0.550 0.0001214 	0.99	(0.97	-	1.02) 0.911 0.0000039
0.2 0.99	(0.98	-	1.01) 0.939 0.0000019 1.00	(0.98	-	1.02) 0.630 0.0000782 	0.99	(0.96	-	1.01) 0.449 0.0002087
0.3 1.00	(0.98	-	1.01) 0.888 0.0000074 1.00	(0.98	-	1.02) 0.616 0.0000865 0.99	(0.97	-	1.01) 0.668 0.0000622
0.4 1.00	(0.98	-	1.01) 0.944 0.0000017 1.00	(0.98	-	1.02) 0.617 0.0000872 0.99	(0.97	-	1.01) 0.625 0.0000860





PT OR	(95%	C.I.) P	value Multiple-R
2
0.0001 1.00	(0.99	-	1.00) 0.395 0.0010462
0.001 1.00	(0.99	-	1.00) 0.651 0.0003055
0.01 0.99	(0.99	-	0.99) 0.021 0.0073119
0.05 0.99	(0.99	-	0.99) 0.012 0.0093830
0.1 	0.99	(0.99	-	0.99) 0.031 0.0065578
0.2 0.99	(0.99	-	1.00) 0.085 0.0044892
0.3 0.99	(0.99	-	1.00) 0.247 0.0019534
0.4 0.99	(0.99	-	1.00) 0.297 0.0015843



















PT OR	(95%	C.I.) P	value Multiple-R
2 OR	(95%	C.I.) P	value Multiple-R2 OR	(95%	C.I.) P	value Multiple-R2
0.0001 1.03	(0.98	-	1.08) 0.199 0.0006102 1.04	(0.97	-	1.12) 0.213 0.0009143 1.00	(0.95	-	1.05) 0.908 0.0000124
0.001 1.06	(1.01	-	1.11) 0.014 0.0022633 1.08	(1.01	-	1.16) 0.019 0.0033593 1.01	(0.96	-	1.07) 0.503 0.0004172
0.01 1.04	(0.99	-	1.09) 0.068 0.0012501 1.06	(0.99	-	1.14) 0.089 0.0017803 1.01	(0.95	-	1.06) 0.661 0.0001798
0.05 1.03	(0.98	-	1.08) 0.210 0.0005926 1.02	(0.95	-	1.10) 0.454 0.0003474 1.01	(0.96	-	1.07) 0.484 0.0004593
0.1 1.06	(1.01	-	1.12) 0.011 0.0024902 1.08	(1.00	-	1.16) 0.036 0.0027897 1.02	(0.96	-	1.07) 0.448 0.0005537
0.2 1.05	(1.00	-	1.10) 0.052 0.0014365 1.05	(0.97	-	1.13) 0.162 0.0012461 1.02	(0.96	-	1.08) 0.410 0.0006289
0.3 1.05	(1.00	-	1.10) 0.038 0.0015548 1.06	(0.98	-	1.14) 0.114 0.0015979 1.01	(0.96	-	1.07) 0.562 0.0002994
0.4 1.05	(1.00	-	1.10) 0.046 0.0015313 	1.05	(0.98	-	1.14) 0.135 0.0013779 1.02	(0.96	-	1.07) 0.442 0.0005551




PT OR	(95%	C.I.) P	value Multiple-R
2 OR	(95%	C.I.) P	value Multiple-R2
0.0001 1.03	(0.98	-	1.08) 0.236 0.0008901 1.01	(0.97	-	1.05) 0.541 0.0002301
0.001 1.08	(1.03	-	1.14) 0.001 0.0062337 1.00	(0.96	-	1.04) 0.880 0.0000136
0.01 	1.04	(0.99	-	1.09) 0.098 0.0016945 1.01	(0.97	-	1.06) 0.387 0.0004716
0.05 	1.03	(0.98	-	1.08) 0.235 0.0009115 	0.99	(0.95	-	1.04) 0.864 0.0000195
0.1 1.07	(1.01	-	1.13) 0.011 0.0040440 1.01	(0.96	-	1.05) 0.600 0.0001718
0.2 1.06	(1.00	-	1.12) 0.026 0.0031548 0.99	(0.94	-	1.03) 0.776 0.0000517
0.3 1.06	(1.00	-	1.12) 0.023 0.0032732 0.99	(0.95	-	1.04) 0.979 0.0000005
0.4 1.06	(1.00	-	1.11) 0.030 0.0029591 	0.99	(0.95	-	1.04) 0.935 0.0000045




PT OR	(95%	C.I.) P	value Multiple-R
2 OR	(95%	C.I.) P	value Multiple-R2 OR	(95%	C.I.) P	value Multiple-R2
0.0001 0.33	(0.09	-	1.17) 0.088 0.0005096 0.30	(0.04	-	2.27) 0.244 0.0057056 0.46	(0.15	-	1.39) 0.163 0.0069638
0.001 0.89	(0.25	-	3.14) 0.856 0.0000568 0.77	(0.10	-	6.02) 0.809 0.0002435 1.03	(0.35	-	3.03) 0.950 0.0000146
0.01 	0.79	(0.22	-	2.81) 0.727 0.0002347 0.08	(0.01	-	0.68) 0.020 0.0220869 3.50	(1.23	-	9.91) 0.018 0.0204857
0.05 1.00	(0.28	-	3.53) 0.995 0.0000000 0.12	(0.01	-	0.98) 0.048 0.0163175 3.47	(1.20	-	10.01) 0.021 0.0195131
0.1 1.01	(0.28	-	3.62) 0.974 0.0000016 0.09	(0.01	-	0.85) 0.033 0.0184389 0.88	(0.86	-	6.80) 0.100 0.0104711
0.2 0.90	(0.25	-	3.21) 0.868 0.0000499 0.11	(0.01	-	0.96) 0.047 0.0165549 0.75	(0.73	-	6.12) 0.166 0.0072132
0.3 1.46	(0.41	-	5.20) 0.566 0.0006729 0.31	(0.03	-	2.78) 0.298 0.0045990 1.71	(0.60	-	4.91) 0.317 0.0038272
0.4 1.69	(0.47	-	6.02) 0.420 0.0012775 0.44	(0.04	-	3.97) 0.471 0.0022266 1.65	(0.57	-	4.76) 0.342 0.0033183














6	months	prior	 to	 their	worst	episode	of	depression,	which	was	significantly	higher	 than	 the	
mean	number	of	1.46	(s.d.	1.37)	reported	by	other	cases	(n=889)	(P	=	5.09	x	10-6).		Analysis	of	
gene-environment	 correlations	 excluding	 cases	 who	 were	 severely	 depressed	 at	 interview	
(n=889	remaining),	no	longer	showed	any	significant	associations	between	polygenic	scores	and	








In	 the	 childhood	 trauma	 sample,	 individuals	 who	 were	 severely	 depressed	 at	 the	 time	 of	




PT OR	(95%	C.I.) P	value Multiple-R
2
0.0001 1.02	(0.95	-	1.08) 0.495 0.0005121
0.001 1.07	(1.01	-	1.15) 0.017 0.0061994
0.01 1.00	(0.94	-	1.07) 0.857 0.0000377
0.05 1.02	(0.96	-	1.09) 0.398 0.0008279
0.1 1.04	(0.98	-	1.11) 0.173 0.0021377
0.2 1.03	(0.96	-	1.10) 0.355 0.0009858
0.3 1.03	(0.96	-	1.10) 0.305 0.0011947
0.4 1.03	(0.96	-	1.10) 0.351 0.0009694
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The persistence of common, heritable psychiatric disorders that reduce reproductive fitness
is an evolutionary paradox. Here, we investigate the selection pressures on sequence
variants that predispose to schizophrenia, autism, bipolar disorder, major depression and
attention deficit hyperactivity disorder (ADHD) using genomic data from 150,656 Icelanders,
excluding those diagnosed with these psychiatric diseases. Polygenic risk of autism and
ADHD is associated with number of children. Higher polygenic risk of autism is associated
with fewer children and older age at first child whereas higher polygenic risk of ADHD is
associated with having more children. We find no evidence for a selective advantage of a high
polygenic risk of schizophrenia or bipolar disorder. Rare copy-number variants conferring
moderate to high risk of psychiatric illness are associated with having fewer children and are
under stronger negative selection pressure than common sequence variants.
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Psychiatric disorders present a paradox which has longpuzzled researchers. Mental illness usually begins in earlyreproductive age and those affected have fewer children
than those unaffected by severe mental illness1,2. This, along
with the substantial heritability and prevalence of psychiatric
disorders, raises the question of why variants that increase the
risk of such diseases have not been purged from the gene pool3,4.
The reasons by which susceptibility alleles for mental
disorders persist in the population remain elusive, but three key
mechanisms have been proposed. Mutation-selection balance
postulates that selection against deleterious sequence variants is
balanced by the continuous occurrence of new mutations2,3,5.
Balancing selection suggests that variants that predispose to
psychiatric disorders may be beneficial under some
circumstances, compensating for the deleterious effects
attributable to these disorders2,3,5. A third possibility is an
accumulation of common variants with effects on psychiatric
disorders that are individually too weak to be effectively targeted
by negative selection in most human populations6.
Rare recurrent copy-number variants (CNVs) with large effects
have been associated with schizophrenia, autism and bipolar
disorder in a subset of patients7,8. Two such CNVs have been
associated with decreased reproductive fitness in carriers in the
general population, with male fitness being particularly affected9.
The persistence of these CNVs in the gene pool is consistent with
mutation-selection balance. However, psychiatric disorders also
have a polygenic component, arising from the combined effect of
many common risk variants, each with small effect4. Polygenic
risk scoring is a method of summarizing an individual’s genetic
liability for a trait, by weighting alleles according to effect sizes
estimated in genome-wide association studies (GWAS)10. These
effects are summed together into a polygenic risk score (PRS),
that reflects the cumulative impact of many common variants on
a phenotype.
Association between PRS for psychiatric disorders and having
fewer children in undiagnosed individuals from the general
population would indicate that common risk variants are subject
to negative selection. Association between PRS and having more
children in individuals unaffected by psychiatric disorders would
support balancing selection. Lack of association between PRS and
number of children would indicate that there is either no
selection affecting these variants or weak selection pressure which
currently cannot be detected. Here, we test these hypotheses
using data from a sample of 150,656 Icelanders representing
approximately half of the population. CNVs implicated in autism
and schizophrenia are also tested for association with number of
children in carriers in the general population, to compare the
selection pressures on the common and rare components of the
genetic basis of psychiatric disorders. Finally, we determine
whether PRS for psychiatric disorders are associated with age at
first child in the Icelandic population, to further dissect the link
between parental age and risk of psychiatric disorders11,12.
Our data show that polygenic risk for autism is associated with
fewer children and later age at first child, while polygenic risk for
ADHD is associated with having more children. We find no
evidence for a selective advantage of high polygenic risk for
schizophrenia or bipolar disorder. Rare CNVs conferring
moderate to high risk of psychiatric illness are associated with
having fewer children and are under stronger negative selection
pressure than common genetic variants.
Results
PRS and psychiatric disorders. PRS for five psychiatric disorders
were generated for each genotyped individual using the results of
independent GWAS on schizophrenia, bipolar disorder, autism,
attention deficit hyperactivity disorder (ADHD) and major
depression, available online from the Psychiatric Genomics
Consortium (https://pgc.unc.edu/)13–17. We first tested the
predictive power of each PRS for their corresponding disorder
within the Icelandic sample. All scores were significantly
associated with their matching disorder (Fig. 1). The maximum
variance explained was 6.4% for schizophrenia
(P¼ 2.1" 10# 109). Other PRS explained up to 0.6% of the
variance for the corresponding diseases (Fig. 1).
PRS and number of children. We used a subset of 93,720
genotyped subjects, aged at least 45 years and without a diagnosis
of a psychiatric disorder, to test the association of each PRS with
the number of children born to each individual. There was a
negative association between the PRS for autism and number of
children (b¼ # 0.25, P¼ 0.002) (Table 1), while higher PRS for
ADHD was associated with having more children (b¼ 0.15,
P¼ 0.002) (Table 1). Other PRS were not associated with number
of children after Bonferroni correction for multiple tests (Table 1,
Supplementary Figs 1–5). The quadratic effects of the PRS were
also examined, to test whether very high or low PRS may be
associated with number of children, but these results were non-
significant. Furthermore, there were no associations between
variance in number of children and deciles of PRS in the total
sample, males or females, after multiple testing correction
(Supplementary Figs 6–10).
Neuropsychiatric CNVs and number of children. In a subset of
patients with schizophrenia or autism, CNVs are likely to be the
strongest individual factors contributing to the pathogenesis of
the disorder. Eleven CNVs conferring risk of schizophrenia or
autism (‘neuropsychiatric CNVs’) were tested for association
with number of children, excluding individuals with autism,
schizophrenia, bipolar disorder and intellectual disability7,8.
Collectively, carriers of a neuropsychiatric CNV (N¼ 469) had
significantly fewer children than non-carriers (N¼ 91,987)
(b¼ # 0.279, P¼ 0.0001), with a greater reduction in males
than females (Table 2). After correction for multiple comparisons,
the 16p11.2 deletion was individually associated with having
fewer children (Table 2).
Selection pressures on PRS versus neuropsychiatric CNVs.
Individuals in the top 1% of schizophrenia PRS have an odds
ratio of 9.5 (95% CI 6.8# 13.3) of developing the disorder. While
this risk is of a magnitude similar to that conferred by a
single neuropsychiatric CNV, individuals with high PRS of
schizophrenia have the same number of children as the rest of the
population (b¼ 0.054, P¼ 0.29). However, they have a greater
variance in number of children (b¼ 1.112, P¼ 0.02). The same
comparison was performed for individuals in the top 1% of PRS
for autism and bipolar disorder. The difference in number of
children was not statistically significant in the former
(b¼ # 0.085, P¼ 0.095, OR for autism¼ 2.4) while those in the
top 1% of bipolar disorder PRS were found to have fewer children
than the rest of the population (b¼ # 0.148, P¼ 0.0037, OR for
bipolar disorder¼ 1.6).
PRS and age at first child. PRS for autism is associated with later
age at first child in the total sample (b¼ 0.97, P¼ 0.0004)
(Table 3). PRS for ADHD is associated with younger age at first
child for both sexes (b¼ # 0.59, P¼ 0.0003) and PRS for MDD
is associated with younger age at first child in females
(b¼ # 0.56, P¼ 0.00009) (Table 3). Quadratic effects of PRS
were not found to be associated with age at first child.
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Here we have investigated selection pressures acting on sequence
variants conferring risk of psychiatric disorders in
recent generations of Icelanders by testing whether PRSs and
neuropsychiatric CNVs are associated with number of children in
a large population sample that excludes patients diagnosed with
the psychiatric diseases. PRS for autism was found to be
associated with having fewer children, indicating that common
variants that are thousands of years old are currently subject to
weak negative selection pressure.
Balancing selection as an explanation for the persistence of
these variants means that variants that increase the risk of
psychiatric disorders may persist if their negative effects on fitness
in affected carriers are offset by benefits in individuals who carry
the variants but do not develop the disorders3. PRS for
schizophrenia and bipolar disorder have been found to predict
creativity in the general population of Iceland18. However,
creative individuals in Iceland have fewer children than
population controls18. Based on these results, along with the
lack of association between these PRS and number of children
found here, we conclude that there is no evidence for a selective
advantage that maintains common variants associated with
schizophrenia or bipolar disorder. While greater PRS for
ADHD is associated with having more children in the Icelandic
population, we do not interpret this as support for balancing
selection. This is because individuals with ADHD have more
children than average in Iceland and in other populations19.
We recognize that a Bonferroni correction may be
over-conservative for this analysis, as one and the same variant
may predispose to several psychiatric disorders, meaning that the
PRS are not totally independent20,21. Furthermore, several of
these PRS currently only explain a small amount of variance in
risk of the disorders themselves (Fig. 1) and therefore may be
underpowered to detect associations with number of children,
even in this large population sample. As GWAS with greater
statistical power are conducted on psychiatric disorders and their
polygenic component can be estimated with greater accuracy,
other associations with reproductive fitness may be uncovered.
One limitation of the current study is that selection pressures in
the modern environment may not be the same as those that acted
on our ancestors. For example, in recent times there have been
far-reaching cultural changes in factors such as education and the
use of contraception, which have led to a postponement of having
a first child and a reduction in number of children in many
human populations. In our data, subjects diagnosed with
psychiatric disorders were excluded. However, some
unidentified patients in the sample could obscure evidence for
balancing selection.
Here, neuropsychiatric CNVs implicated in schizophrenia,
autism and bipolar disorder are associated with fewer children,
particularly among males. These CNVs are rare and generally
have large effects7,8. Several have been associated with lower IQ,
cognitive deficits and other physical abnormalities, that may have
a negative impact on reproductive fitness in population controls
Table 1 | Association between polygenic risk scores and number of children.
Total population Males FemalesPolygenic score
P value Beta (CI) P value Beta (CI) P value Beta (CI)
ADHD 0.002 0.15 (0.05, 0.25) 0.170 0.09 (!0.04, 0.24) 0.002 0.20 (0.07, 0.33)
Autism 0.002 !0.25 (!0.41, !0.09) 0.003 !0.36 (!0.59, !0.12) 0.130 !0.16 (!0.38, 0.05)
Bipolar disorder 0.740 !0.005 (!0.03, 0.02) 0.500 0.01 (!0.02, !0.05) 0.310 !0.02 (!0.05, 0.01)
Major depression 0.170 0.04 (!0.01, 0.11) 0.650 0.02 (!0.07, 0.12) 0.094 0.07 (!0.01, 0.16)
Schizophrenia 0.160 0.006 (!0.002, 0.01) 0.530 0.004 (!0.008, 0.02) 0.170 0.007 (!0.003, 0.02)
































Figure 1 | Polygenic risk scores for psychiatric disorders predict their corresponding disorder in the general population of Iceland. The x axis shows the
seven P-value parameters (0.001, 0.003, 0.01, 0.03, 0.1, 0.3 and 1.0) used to weight SNPs from the discovery GWAS plotted left to right. The y axis
indicates the Nagelkerke’s pseudo-R2 measure of variance explained.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15833 ARTICLE
NATURE COMMUNICATIONS | 8:15833 |DOI: 10.1038/ncomms15833 | www.nature.com/naturecommunications 3
	 51	
	
who have not been diagnosed with psychotic or
neurodevelopmental disorders9,22. De novo CNVs have been
implicated in cases of schizophrenia, autism and bipolar disorder
which supports mutation-selection balance. A previous study
has also shown that there is a strong selection against
schizophrenia-associated CNVs, such that these variants persist
in the population for only a few generations after they arise23.
Finally, age at first child is of particular interest as Western
society has experienced a rapid postponement of parenthood24,
which has been associated with reduction in polygenic score for
educational attainment25. Delayed fatherhood has been linked to
risk of psychiatric disorders, widely assumed to be caused by the
accumulation of de novo mutations in the spermatogonial stem
cells of older males26,27. However, recent population genetic
modelling suggests that these mutations are unlikely to explain
much of the risk and a weak correlation between age at first child
and genetic liability to psychiatric illness could account for the
observed incidence of the disorders in the children of older
fathers11. In accordance with this hypothesis, PRS for autism was
positively associated with later age at first child in the Icelandic
population, providing an alternative explanation of age-related
mutations.
In summary, our results show that common sequence variants
conferring risk of autism and ADHD are currently under weak
selection in the general population of Iceland. However, rare
CNVs that also impact cognition are under stronger selection
pressure, consistent with mutation-selection balance. The
hypothesis that a selective advantage accounts for the prevalence
of sequence variants conferring risk of schizophrenia and bipolar
disorder is unproven, but rather this empirical evidence suggests
that common sequence variants largely escape selection as their
individual effect sizes are weak.
Methods
Subjects. The study was approved by the National Bioethics Committee of
Iceland and the Icelandic Data Protection Authority. Samples are from a
population genetic biobank of 150,656 Icelanders established by deCODE genetics.
Reproductive fitness was defined as the number of children born to individuals
over 45 years. Subjects born before 1968 with matching genotypic data
(N¼ 93,720) were identified from deCODE’s nation-wide genealogy database.
This contains information on year of birth, county of birth and numbers of
children of Icelanders. Diagnoses of schizophrenia and bipolar disorder were
assigned according to Research Diagnostic Criteria (RDC)28 through the use of the
Schedule for Affective Disorders and Schizophrenia Lifetime Version (SADS-L)29.
ADHD subjects were recruited from outpatient pediatric, child and adult
psychiatry clinics in Iceland; ICD-10 diagnoses were made on the basis of
standardized diagnostic assessments by experienced clinicians. Autism subjects
were ascertained through the State Diagnostic Counseling Center and the
Department of Child and Adolescent Psychiatry in Iceland and received ICD-10
diagnoses based on standardized diagnostic assessments by clinical specialists.
Diagnoses of MDD were made by clinicians or based on the results of a
semi-structured interview (CIDI), and were assigned according to DSM-III, ICD-9
or ICD-10 criteria. All diagnoses of recurrent depression were included (that is,
mild, moderate and severe), but in the case of single episode depression mild cases
were excluded. Characteristics of the sample are shown in Supplementary Table 1.
Genotyping and imputation. Genotyping was performed on Illumina HumanHap
(300, 370, 610, 1 M, 2.5 M) and IlluminaOmni (670, 1 M, 2.5 M, Express) SNP
arrays9. BeadStudio (Illumina; version 2.0) was used to call genotypes, normalize
signal intensity data and establish the log R ratio and B allele frequency at every
SNP. Long-range haplotype phasing was achieved using an iterative algorithm,
which phases a single proband at a time, given the available phasing information
on all other individuals who share a long haplotype identically by state with the











All CNVs 201/268 42,826/49,161 "0.405/"0.184 0.00028/0.050
Autism CNVs 37/60 42,990/49,369 " 1.263/"0.481 9.4E"07/0.014
Schizophrenia CNVs 189/256 42,838/49,173 "0.266/"0.115 0.021/0.23
16p11.2 del inf/NA 12/12 43,015/49,417 " 2.534/" 1.59 1.8E"08/0.00025
1q21.1 del NA/8.35 11/15 43,016/49,414 "0.741/"0.98 0.12/0.012
22q11.21 del NA/inf 3 92,453 " 1.421 0.11
16p11.2 dup 4.1/11.52 39 92,417 "0.326 0.19
15q11.2—13.1 dup inf/13.20 4 92,452 "0.926 0.23
7q11.23 (WBS) dup NA/11.35 3 92,453 " 1.150 0.23
15q13.3 all del inf/7.52 19 92,437 "0.343 0.34
16p13.1 dup NA/2.30 103 92,353 "0.128 0.41
2p16.1 (NRXN1) del 5.6/9.01 11 92,445 "0.353 0.45
15q11.2 all del NA/2.15 192 92,264 "0.058 0.61
1q21.1 dup NA/3.45 38 92,418 0.049 0.85
Results are shown in males and females separately when there is a significant (Po0.05) association in either group. Counting all models fitted, 28 tests were performed; thus the significance threshold is
Po0.0017. Odds ratios for autism and schizophrenia are from the literature7,8.
Table 3 | Association between polygenic risk scores and age at first child.
Total sample Males FemalesPolygenic score
P value Beta (CI) P value Beta (CI) P value Beta (CI)
ADHD 0.0003 "0.59 ("0.92, "0.26) 0.07 "0.48 ("0.99, "0.03) 0.0005 "0.71 (" 1.12, "0.31)
Autism 0.0004 0.97 (0.43, 1.51) 0.03 0.91 (0.08, 1.76) 0.001 1.10 (0.45, 1.77)
Bipolar disorder 0.005 0.14 (0.04, 0.23) 0.18 0.10 ("0.04, 0.25) 0.007 0.16 (0.04 " 0.28)
Major depression 0.006 "0.31 ("0.54, "0.09) 0.71 "0.06 ("0.42, 0.28) 9.00E"05 "0.56 ("0.84, "0.28)
Schizophrenia 0.07 "0.02 ("0.05, 0.003) 0.81 "0.005 ("0.05, 0.04) 0.02 "0.04 ("0.07, "0.01)
In total, ten tests on age at first child were performed; thus the significance threshold is Po0.005.
CI—95% confidence interval
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15833
4 NATURE COMMUNICATIONS | 8:15833 | DOI: 10.1038/ncomms15833 | www.nature.com/naturecommunications
	 52	
	
proband30. Given the large proportion of the Icelandic population that has been
chip-typed, accurate genome-wide long-range phasing is possible for all chip-typed
Icelanders. For long-range phased haplotype association analysis, the genome was
then partitioned into non-overlapping fixed 0.3 cm bins. Within each bin, the
haplotype diversity was consistent with the combination of all chip-typed markers
in the bin. The whole genomes of 8,453 Icelanders were sequenced using Illumina
technology to a mean depth of at least ! 10 (median ! 32). SNPs and indels were
identified and genotypes called using join calling with the Genome Analysis
Toolkit Haplotype Caller (GATK version 3.3.0) (ref. 31). The error rate of genotype
calls made solely on the basis of next generation sequence data decreases as a
function of sequencing depth. Taking advantage of the fact that all the sequenced
individuals had also been chip-typed and long-range phased, information about
haplotype sharing was utilized to minimize the number of such errors.
Thus, the genotype call in cases where sequence reads were ambiguous would be
informed by comparison with sequence reads of other individuals sharing
haplotypes with the individual in question at the ambiguous site. To improve
genotype quality and to phase the sequencing genotypes an iterative algorithm
based on the IMPUTE HMM model32 and using the long range phased haplotypes
was employed33. The same principle was then used to impute the sequence variants
identified in the 8,453 sequenced Icelanders into 150,656 Icelanders who had been
genotyped with various Illumina SNP arrays and their genotypes phased using
long-range phasing33.
Polygenic risk scoring and CNV selection. We derived PRSs from GWAS
summary results available online from the Psychiatric Genomics Consortium
(https://pgc.unc.edu/) for ADHD, autism, bipolar disorder, major depression and
schizophrenia13–17. The number of cases in these studies was 896, 3,303, 7,481,
9,240 and 35,476 respectively. The deCODE sample was not part of these analyses.
To compute the PRSs we used approximately 630,000 autosomal markers from a
framework set of markers used in long-range haplotype phasing. The
framework markers have been selected on the basis of various quality criteria
including high genotype yield, Hardy–Weinberg equilibrium and consistency of
allele frequencies across different Illumina array types. We estimated the linkage
disequilibrium between markers using Icelandic samples and adjusted for it using
LDpred34 a recently proposed method. PRSs were calculated with seven different
settings of the P parameter (corresponding roughly to the fraction of causal
markers34): 0.001, 0.003, 0.01, 0.03, 0.1, 0.3 and 1.0. Eleven CNVs conferring risk of
schizophrenia or autism (‘neuropsychiatric CNVs’) were selected from the most
recent review on CNVs in schizophrenia7 and the most recent analysis of CNVs in
autism8.
Statistical analysis. PRSs were first tested for association with their corre-
sponding psychiatric disorder in the Icelandic population (N¼ 1,137, 692, 806,
3,246 and 631 cases for ADHD, autism, bipolar disorder, major depression and
schizophrenia respectively). This was performed using logistic regression with five
principal components as covariates. Models were compared against a null model
including covariates only to calculate the Nagelkerke’s pseudo-R2 measure of
variance explained. A linear mixed effects model was used to test the association of
number of children with PRS for the five psychiatric disorders. Number of children
was regressed on the PRS of interest, covarying for year of birth, sex and interaction
between the two, birth county of last child or birth county of the parent, five
principal components and sibship (to account for relatedness). For each respective
disorder we chose the PRS calculated with a P parameter corresponding to a
fraction of causal markers of 0.3 and modelled the correlation with its respective
disorder and then recalibrated the PRS to have a mean of 0 and a unit increase
corresponding to a doubling of risk for the disorder. All predictors were modelled
as fixed effects apart from sibship which was random. This model was compared
against a null model including the covariates only. To test the quadratic effects of
the PRS, a PRS squared term was added and PRS was included in the null model.
Sex-specific analyses were also conducted. Individuals diagnosed with each
psychiatric disorder were excluded, although it may not be possible to identify
every past case in a general population sample. Age at first child was tested for
association with each PRS in the same manner. To examine the relationship
between variance in number of children and PRSs, PRSs were split into deciles and
number of children was adjusted for all covariates. A linear regression was used to
test the association between deciles of PRS and residual number of children in the
total sample, males and females. Neuropsychiatric CNVs were examined for
association with number of children using the following covariates: year of birth,
sex and interaction between the two, birth county of last child or birth county of
the parent, five principal components and the random effect of sibship. Individuals
with autism, schizophrenia, bipolar disorder and intellectual disability were
excluded from the CNV analyses.
Data availability. Data supporting the findings of this study are available within
the article and its Supplementary Information files. Summary level data from the
PGC GWAS used to calculate PRS in this study were obtained from the PGC
Downloads website (https://www.med.unc.edu/pgc/results-and-downloads/).
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Background:	 Suicide	 is	 a	worldwide	 public	 health	 problem	 and	 the	 second	 leading	 cause	 of	
death	 among	 young	 adults.	 Over	 90%	 of	 suicide	 attempters	 or	 victims	 have	 a	 psychiatric	
diagnosis,	however	twin	and	family	studies	suggest	that	the	genetic	aetiology	of	suicide	attempt	
is	partially	distinct	from	that	of	the	psychiatric	disorders	themselves.	Genome-wide	association	
studies	 (GWAS)	 to	 date	 have	 failed	 to	 identify	 replicable	 genetic	 associations	 with	 suicide	



































and	 rates	of	 suicide	are	 far	exceeded	by	 suicide	attempts,	which	occur	up	 to	20	 times	more	
frequently	 (World	 Health	 Organization,	 2014).	 This	 represents	 a	 huge	 personal,	 social	 and	
economic	burden,	with	the	Centers	for	Disease	Control	and	Prevention	reporting	that	suicide	
costs	the	US	economy	$51	billion	per	year	in	healthcare	and	work-loss	related	costs	(Centers	for	
Disease	 Control	 and	 Prevention,	 2015).	 These	 stark	 figures	 highlight	 the	 urgent	 need	 for	
improved	 prevention	 and	 treatment,	 however	 progress	 has	 been	 hampered	 by	 the	 lack	 of	
reliable	methods	for	predicting	suicidality	and	a	poor	understanding	of	its	biological	aetiology.	
		
Over	 90%	 of	 suicide	 attempters	 or	 victims	 have	 a	 psychiatric	 disorder,	 particularly	 mood	
disorders,	 schizophrenia	and	substance	use	disorders	 (Qin,	2011,	Beautrais	et	al.,	1996).	The	
heritability	 estimate	 of	 suicidal	 behaviour	 from	 twin	 studies	 is	 30-55%	 and	 twin	 and	 family	
studies	suggest	that	the	genetic	aetiology	of	suicide	attempt	is	partially	distinct	from	that	of	the	
psychiatric	 disorders	 themselves	 (Voracek	 and	 Loibl,	 2007,	 Brent	 and	Mann,	 2005).	 Several	
genome-wide	 association	 studies	 (GWAS)	 have	 been	 conducted	 on	 suicide	 attempt,	 by	
comparing	attempters	versus	non-attempters	with	depression	or	bipolar	disorder,	 to	test	 for	
genetic	variants	contributing	independently	to	suicide	attempt	(Willour	et	al.,	2012,	Schosser	et	
al.,	 2011,	 Perlis	 et	 al.,	 2010,	Mullins	 et	 al.,	 2014).	 These	 studies	 have	 failed	 to	 identify	 any	
replicable	genetic	associations,	likely	due	to	limited	sample	sizes	which	were	underpowered	to	
detect	the	small	genetic	effects	typical	for	a	single	SNP.	Other	GWAS	have	focused	on	subjects	





association	with	 suicide	 attempt	 in	 an	 independent	 sample,	 consistent	with	 the	presence	of	













Only	cases	affected	with	psychiatric	disorders	were	 included	 in	 this	 study	and	all	 cases	were	
defined	 using	 structured	 psychiatric	 interviews	 according	 to	 international	 consensus	 criteria	
(DSM-IV,	ICD-9,	or	ICD-10)	(American	Psychiatric	Association,	1994,	World	Health	Organization,	











and	 imputation	 were	 performed	 centrally	 using	 the	 PGC	 ‘Ricopili’	 pipeline	
(https://sites.google.com/a/broadinstitute.org/ricopili/),	 for	 each	 cohort	 separately.	 These	
procedures	 have	 been	 described	 in	 detail	 previously	 (Schizophrenia	 Working	 Group	 of	 the	





0.01.	 Genotype	 imputation	 was	 performed	 using	 the	 pre-phasing/	 imputation	 stepwise	
approach	implemented	in	IMPUTE2/	SHAPEIT	(chunk	size	of	3	Mb	and	default	parameters)	to	









each	 cohort	 separately	 (Chang	 et	 al.,	 2015).	 Five	 principal	 components,	 generated	 using	
EIGENSTRAT	were	used	as	covariates	in	all	GWAS	to	control	for	population	stratification	(Price	
et	 al.,	 2006).	 There	 was	 no	 evidence	 of	 stratification	 artifacts	 or	 uncontrolled	 test	 statistic	
inflation	 in	 the	 results	 from	 any	 cohort	 (e.g.	 λGC	 was	 0.87	 -	 1.01).	 Within	 each	 psychiatric	
disorder,	meta-analysis	of	the	results	from	all	cohorts	was	performed	using	an	inverse-weighted	




control	 model,	 the	 Genetic	 Power	 Calculator	 was	 used	 to	 determine	 the	 power	 to	 detect	
associations	at	genome-wide	significance	(P	<	5	x	10-8),	for	the	meta-analysis	of	6,569	suicide	




Polygenic	 risk	scoring	was	used	to	 test	 for	genetic	overlap	between	suicide	attempt	 in	 these	
psychiatric	disorders.	The	results	of	three	GWAS	(SA	in	MDD,	SA	in	BIP	and	SA	in	SCZ)	were	used	












logistic	 regression.	 The	 regression	 model	 also	 included	 five	 principal	 components	 and	 a	
covariate	for	each	cohort	in	the	test	dataset.	The	amount	of	variance	explained	by	the	PRS	was	





The	 variance	 in	 suicide	 attempt	 explained	 by	 genotyped	 SNPs	 (SNP	 heritability,	 ℎ"#$% )	 was	
assessed	 using	 genomic-relatedness-based	 restricted	 maximum-likelihood	 (GREML),	
implemented	in	GCTA	software	(Yang	et	al.,	2011).	The	SNP	probabilities	were	converted	to	best	
guess	data	with	a	genotype	call	probability	cut-off	of	0.8.	HapMap	3	SNPs	with	an	INFO	score	≥	
0.6	 were	 used	 to	 calculate	 the	 genetic	 relatedness	 matrix	 (GRM)	 using	 PLINK2,	 including	

























the	 ARL5B	 (ADP-Ribosylation	 Factor-Like	 5B)	 gene.	 An	 insertion-deletion	 polymorphism	 on	
chromosome	4	met	genome-wide	significance	in	the	GWAS	of	suicide	attempt	in	BIP,	with	the	












Major	depressive	disorder	 16	 1622	(16%)	 8786	(84%)	 1155	(71%)	 5808	(66%)	
Bipolar	disorder	 21	 3264	(37%)	 5500	(63%)	 2097	(66%)	 2971	(56%)	
Schizophrenia	 9	 1683	(36%)	 2946	(64%)	 660	(39%)	 924	(31%)	
Total	 	 6569	(28%)	 17232	(72%)	 3912	(60%)	 9703	(56%)	
	 71	
direction	of	effect	highly	consistent	across	the	21	BIP	cohorts:	chr4_23273116_D,	P	=	1.15x10-8,	






from	the	meta-analysis	of	 suicide	attempt	 in	mood	disorders.	 In	 this	analysis,	 there	were	10	
genome-wide	 significant	 SNPs	 from	 two	 independent	 loci	 (Table	2).	 The	 top	association	was	
rs138689899	on	chromosome	2,	P	=	2.50	x	10-8,	OR	T	allele	=	1.75.	This	 is	an	 intergenic	SNP	
between	the	IWS1	and	MYO7B	genes.	The	other	significant	locus	was	on	chromosome	4	and	is	
also	 in	 LOC105374524.	 It	 is	 in	 high	 LD	 (R2=	 0.83)	 with	 the	 insertion-deletion	 polymorphism	
identified	in	the	GWAS	of	SA	in	BIP.	The	most	significant	SNP	was	rs28591567,	P	=	3.11	x	10-8,	
OR	G	allele	1.19	(Table	2).	Figure	2	is	a	regional	association	plot	of	LOC105374524	showing	P	
values	 from	 the	 meta-analysis	 of	 suicide	 attempt	 in	 mood	 disorders.	 This	 locus	 was	 not	
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and	 non-attempters	 across	 three	major	 psychiatric	 disorders,	 recruited	 from	 the	 Psychiatric	















The	UK	 Biobank	 Study,	which	 is	 a	 large	 population-based	 genetic	 study	 of	 disease,	will	 also	
provide	data	from	a	mental	health	questionnaire	(Sudlow	et	al.,	2015).	This	will	include	a	wealth	




The	meta-analysis	 of	 suicide	 attempt	 across	 all	 three	 psychiatric	 disorders	 found	 no	 genetic	










of	 these	 approaches	 have	 their	merits,	 as	 large	 samples	 sizes	 can	 increase	 statistical	 power	
despite	heterogeneity	(Mullins	and	Lewis,	2017).		
	
The	within-case	 comparison	of	 attempters	 versus	non-attempters	used	 for	 these	GWAS	was	
utilised	to	detect	associations	specific	for	suicide	attempt	and	was	informed	by	twin	and	family	
studies	 which	 consistently	 indicate	 a	 genetic	 component	 to	 suicide	 attempt	 which	 is	
independent	of	the	psychiatric	disorders	themselves	(Voracek	and	Loibl,	2007,	Brent	and	Mann,	
2005).	 Several	 twin	 studies	 have	 calculated	 that	 suicide	 attempt	 is	 moderately	 heritable,	




The	 Diagnostic	 and	 Statistical	 Manual	 of	 Mental	 Disorders	 5th	 edition	 (DSM-5)	 lists	 Suicidal	
Behavior	 Disorder	 as	 a	 condition	 for	 further	 study	 and	 this	 nomenclature	 and	 clear	 criteria	
should	lead	to	improved	identification	and	documentation	of	this	serious	condition,	which	will	
aid	 patient	 care	 and	 future	 research	 (American	 Psychiatric	 Association,	 2013).	 The	 subjects	
included	in	this	study	were	not	ascertained	primarily	for	suicide	attempt	and	therefore	detailed	





large	 sample	 sizes	 required	 for	 robust	 genetic	 studies	 on	 this	 phenotype.	 However,	 further	
increases	in	sample	size	are	essential	to	fully	interrogate	the	common	genetic	architecture	of	
suicide	attempt	and	 this	will	necessitate	 increased	collaboration.	There	 is	an	urgent	need	 to	
better	 understand	 the	 aetiology	 of	 suicide	 attempt	 and	 this	GWAS	makes	 initial	 progress	 in	
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Table	S8:	Top	20	results	from	GWAS	of	suicide	attempt	in	major	depressive	disorder	showing	the	most	significant	SNP	from	each	genomic	region







rs45593736 10 18954937 A/G 0.02 0.01 2.61E-08 2.38(1.75-3.23) +++?++++-++?+-?+
rs111625585 14 82804332 T/C 0.08 0.06 6.75E-08 1.57(1.33-1.84) +++--+++++-+++-+
rs116428372 16 589359 A/G 0.07 0.06 1.91E-07 1.74(1.41-2.14) ++++++++-+++-+++
rs77033326 4 89777618 A/G 0.03 0.02 2.07E-07 2.24(1.65-3.03) +-++-+-+-++-++++
rs183414028 1 40442026 T/C 0.98 0.99 2.39E-07 0.39(0.27-0.56) ----------+-+---
rs113330417 14 67249421 A/G 0.96 0.98 2.48E-07 0.57(0.46-0.71) ------------+---
rs111367251 7 144968289 C/G 0.98 0.99 3.26E-07 0.45(0.33-0.61) -?-+------+----+
rs62460873 7 84977966 T/C 0.98 0.99 5.01E-07 0.37(0.25-0.54) ?--???-----++---
rs186736781 2 240473090 T/C 0.03 0.02 6.37E-07 2.27(1.64-3.13) +?+?-+-++++-+---
chr15_24344805_D 15 24344805 D/I3 0.37 0.41 7.14E-07 0.79(0.73-0.87) ----------+-+-+-
rs111326206 3 142438431 T/C 0.95 0.97 7.16E-07 0.62(0.51-0.75) -+-----+--+?--+-
chr6_128178230_I 6 128178230 I2/D 0.08 0.06 7.92E-07 1.58(1.32-1.90) --------+-------
rs184924771 11 25885205 A/C 0.98 0.99 8.51E-07 0.39(0.27-0.57) -?-?+--?+-??-?--
rs113386487 10 13358583 A/T 0.97 0.98 9.73E-07 0.47(0.35-0.64) -?-??---?-?+?--+
rs13137453 4 153907879 A/G 0.97 0.98 9.88E-07 0.46(0.34-0.63) -?-?+---?---+---
rs9972552 15 34396913 A/C 0.03 0.02 1.01E-06 2.18(1.59-2.98) +-+++-++++-+++++
rs191852465 7 63164142 T/C 0.96 0.97 1.02E-06 0.46(0.34-0.63) -++-----------+-
chr13_46256859_D 13 46256859 D/I6 0.02 0.01 1.07E-06 2.27(1.63-3.16) --++?+?-++-+++++
rs145440507 4 188400537 A/T 0.98 0.99 1.15E-06 0.37(0.25-0.55) -?-???-??--?-??-
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Table	S10:	Top	20	results	from	GWAS	of	suicide	attempt	in	schizophrenia	showing	the	most	significant	SNP	from	each	genomic	region







rs482039 1 190777567 T/C 0.03 0.02 4.39E-07 2.37(1.70-3.31) +++-+++++
rs3858375 11 95077167 T/C 0.07 0.05 8.99E-07 1.60(1.33-1.94) ++++-++++
rs4843180 16 86753070 T/C 0.44 0.39 1.06E-06 1.25(1.14-1.36) +++++++++
rs180697792 17 67294430 A/G 0.23 0.20 1.43E-06 1.34(1.19-1.50) ++++++-++
rs72756712 9 128902906 A/G 0.93 0.95 2.67E-06 0.60(0.49-0.74) ---------
rs191312301 6 38975727 A/C 0.86 0.89 2.76E-06 0.71(0.62-0.82) --+------
chr2_188481671_D 2 188481671 D/I3 0.34 0.38 4.23E-06 0.79(0.71-0.87) ---------
rs73650494 9 78831443 T/C 0.96 0.98 5.39E-06 0.56(0.43-0.72) ---------
rs6114731 20 24427180 A/G 0.04 0.03 5.46E-06 1.78(1.39-2.27) +++++-+++
rs75305337 3 84333133 A/C 0.12 0.09 5.63E-06 1.39(1.20-1.60) +++++++++
chr11_133764404_I 11 133764404 I5/D 0.79 0.75 5.82E-06 1.29(1.15-1.43) ------+--
rs57729539 15 78524199 A/G 0.80 0.83 6.18E-06 0.76(0.68-0.86) ---+-----
rs875777 7 86745380 T/C 0.16 0.20 6.66E-06 0.76(0.67-0.86) --+------
rs6497871 16 10364163 A/G 0.64 0.60 7.44E-06 1.24(1.13-1.37) +++++++++
rs151336980 11 120470737 T/C 0.04 0.03 7.52E-06 1.78(1.38-2.29) ++++-++-+
rs4494728 2 65589513 T/C 0.50 0.55 7.82E-06 0.82(0.75-0.89) ---------
rs2739958 8 12232534 T/C 0.58 0.60 8.18E-06 0.68(0.57-0.80) --+----+-
rs73215273 13 72403250 A/C 0.88 0.90 8.71E-06 0.66(0.54-0.79) -+-------
rs11739808 5 72745041 A/G 0.03 0.02 8.72E-06 2.30(1.59-3.31) ++-++++++
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Table	S11:	Top	20	results	from	meta-analysis	of	suicide	attempt	in	MDD,	BIP	and	SCZ	showing	the	most	significant	SNP	from	each	genomic	region







rs149268645 2 203833018 A/G 0.14 0.15 4.28E-07 0.85(0.80-0.90) ---
rs4870888 8 125108977 T/C 0.52 0.54 5.00E-07 0.89(0.86-0.93) ---
chr4_23273116_D 4 23273116 D/I 0.19 0.18 5.13E-07 1.16(1.09-1.23) +++
rs141252918 6 151828058 A/G 0.02 0.01 5.76E-07 1.73(1.39-2.14) ++?
rs9577511 13 113991823 A/G 0.86 0.87 5.86E-07 0.83(0.77-0.89) ---
rs62173322 2 170611029 A/G 0.86 0.87 8.13E-07 0.84(0.78-0.90) ---
rs76371172 15 31814455 T/G 0.98 0.98 8.20E-07 0.61(0.50-0.74) ---
rs11004733 10 56849344 T/C 0.04 0.04 1.00E-06 1.34(1.19-1.50) +++
rs138689899 2 128288162 T/C 0.02 0.02 1.61E-06 1.53(1.29-1.82) ++-
rs142055939 3 45995554 T/C 0.02 0.02 1.69E-06 1.48(1.26-1.75) +++
rs35107435 11 27249330 A/T 0.16 0.15 1.70E-06 1.17(1.10-1.24) +++
rs113988902 13 19525105 T/C 0.05 0.04 1.74E-06 1.52(1.28-1.80) ?++
chr13_73243177_I 13 73243177 I/D 0.04 0.03 1.93E-06 1.59(1.32-1.93) ?--
rs186672572 5 116878032 T/C 0.02 0.01 2.11E-06 1.64(1.33-2.00) +++
rs113386487 10 13358583 A/T 0.98 0.98 2.12E-06 0.67(0.56-0.79) ---
rs73348245 14 96158072 A/G 0.06 0.06 2.13E-06 1.27(1.15-1.40) +++
rs6426297 1 246538381 T/C 0.02 0.01 2.22E-06 1.65(1.34-2.04) +++
rs73577700 16 80280761 A/T 0.83 0.85 2.57E-06 0.87(0.82-0.92) ---
rs72756712 9 128902906 A/G 0.94 0.95 2.71E-06 0.78(0.70-0.86) ---




































rs138689899 2 128288162 T/C 0.02 0.01 2.50E-08 1.75(1.44-2.14) ++
rs28591567 4 23253912 A/G 0.78 0.80 3.11E-08 0.84(0.79-0.89) --
chr6_151835609_D 6 151835609 I/D 0.94 0.95 3.66E-07 0.74(0.66-0.83) ++
chr13_61834504_D 13 61834504 I/D 0.91 0.92 5.77E-07 0.78(0.71-0.86) ++
rs186672572 5 116878032 T/C 0.02 0.01 7.19E-07 1.78(1.42-2.24) ++
rs112944737 8 134677667 T/C 0.91 0.92 1.11E-06 0.80(0.73-0.87) --
rs9577511 13 113991823 A/G 0.86 0.87 1.35E-06 0.81(0.75-0.88) --
rs150795632 6 37439376 A/G 0.98 0.98 1.69E-06 0.59(0.48-0.73) --
rs113051785 11 20167807 C/G 0.02 0.01 1.70E-06 1.75(1.39-2.20) ++
rs1355048 1 90830490 T/C 0.37 0.40 1.91E-06 0.88(0.84-0.93) --
rs115833694 4 99918226 C/G 0.98 0.98 1.99E-06 0.63(0.52-0.76) --
rs17764923 6 159820779 A/G 0.16 0.14 2.04E-06 1.19(1.11-1.27) ++
rs117020391 12 107099751 T/C 0.98 0.98 2.09E-06 0.63(0.52-0.76) --
rs72832403 2 115551269 A/G 0.92 0.93 2.16E-06 0.79(0.72-0.87) --
rs150320200 4 23450330 A/G 0.97 0.98 2.19E-06 0.66(0.55-0.78) --
rs114598476 1 224438315 A/G 0.96 0.97 2.30E-06 0.67(0.57-0.79) --
rs76400344 22 26697120 A/C 0.03 0.02 3.01E-06 1.52(1.28-1.82) ++
chr2_124851208_D 2 124851208 I/D 0.96 0.96 3.48E-06 0.72(0.62-0.82) ++
rs143457262 7 82072544 A/G 0.03 0.03 4.16E-06 1.51(1.26-1.79) ++
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Table	S13:	Top	20	results	from	meta-analysis	of	suicide	attempt	in	BIP	and	SCZ	showing	the	most	significant	SNP	from	each	genomic	region







chr4_23273116_D 4 23273116 D/I 0.19 0.17 8.90E-07 1.19(1.11-1.27) ++
rs26318 5 115687905 T/C 0.98 0.99 9.50E-07 0.52(0.40-0.67) --
rs118102650 11 9099847 A/G 0.02 0.01 2.22E-06 1.79(1.41-2.28) ++
rs12925656 16 65107920 T/C 0.88 0.90 3.22E-06 0.82(0.76-0.89) --
rs73122740 7 53695512 T/G 0.92 0.91 3.93E-06 1.26(1.14-1.39) ++
rs2353181 2 170305256 T/C 0.95 0.94 4.61E-06 1.33(1.17-1.49) ++
rs75237141 6 72966596 A/G 0.90 0.92 5.84E-06 0.80(0.73-0.88) --
rs56342621 19 35071781 C/G 0.98 0.99 6.67E-06 0.61(0.49-0.75) --
rs9475195 6 55061018 T/C 0.58 0.61 7.25E-06 0.89(0.84-0.93) --
chr4_82106147_I 4 82106147 I/D 0.07 0.06 7.85E-06 1.29(1.15-1.44) --
chr8_80591790_D 8 80591790 I/D 0.61 0.63 7.95E-06 0.88(0.83-0.93) ++
rs10892827 11 122210990 T/G 0.90 0.92 8.01E-06 0.80(0.73-0.88) --
rs189924441 10 94182243 A/G 0.97 0.97 8.30E-06 0.67(0.56-0.80) --
rs8022689 14 21608986 A/G 0.38 0.35 8.58E-06 1.14(1.07-1.20) ++
rs3007305 1 246862572 C/G 0.66 0.68 8.72E-06 0.88(0.83-0.93) --
rs72924216 6 94570858 A/G 0.95 0.96 9.08E-06 0.72(0.63-0.83) --
rs66666015 19 38717143 T/C 0.76 0.74 9.42E-06 1.16(1.09-1.24) ++
rs38758 7 109943767 A/C 0.47 0.44 9.46E-06 1.12(1.07-1.18) ++
rs117559494 10 98008526 A/G 0.03 0.03 9.50E-06 1.53(1.27-1.85) ++
rs117637007 18 75827605 T/C 0.11 0.13 9.58E-06 0.80(0.72-0.88) --
CHR,	chromosome;	BP,	basepair	position;	freq,	frequency;	OR,	odds	ratio;	CI,	confidence	interval
Table	S14:	Comparison	of	genome-wide	significant	locus	on	chr4	between	GWAS	on	suicide	attempt,	MDD,	BIP	and	SCZ	
GWAS	(References) CHR Variant BP A1 P	value OR	(C.I.)
SA	in	MDD 4 rs28591567 23253912 G 0.030 1.11(1.05-1.18)
SA	in	BIP 4 rs28591567 23253912 G 6.78E-08 1.25(1.15-1.35)
SA	in	SCZ 4 rs28591567 23253912 G 0.674 1.02(0.96-1.09)
MDD	1 4 rs28591567 23253912 G 0.010 0.98(0.97-1.00)
BIP	2 4 rs28591567 23253912 G 0.231 0.98(0.95-1.01)









































Investigation of blood mRNA biomarkers for suicidality in an
independent sample
N Mullins1, K Hodgson1, KE Tansey2, N Perroud3, W Maier4, O Mors5, M Rietschel4,6, J Hauser7, N Henigsberg8, D Souery9,10,
K Aitchison1,11, A Farmer1, P McGufﬁn1, G Breen1,12, R Uher1,13 and CM Lewis1,14
Changes in the blood expression levels of SAT1, PTEN, MAP3K3 and MARCKS genes have been reported as biomarkers of high versus
low suicidality state (Le-Niculescu et al.). Here, we investigate these expression biomarkers in the Genome-Based Therapeutic Drugs for
Depression (GENDEP) study, of patients with major depressive disorder on a 12-week antidepressant treatment. Blood gene
expression levels were available at baseline and week 8 for patients who experienced suicidal ideation during the study (n=20) versus
those who did not (n=37). The analysis is well powered to detect the effect sizes reported in the original paper. Within either group,
there was no signiﬁcant change in the expression of these four genes over the course of the study, despite increasing suicidal ideation
or initiation of antidepressant treatment. Comparison of the groups showed that the gene expression did not differ between patients
with or without treatment-related suicidality. This independent study does not support the validity of the proposed biomarkers.
Translational Psychiatry (2014) 4, e474; doi:10.1038/tp.2014.112; published online 28 October 2014
INTRODUCTION
Suicide is a worldwide public health problem and is among the
ten leading causes of death.1 Suicidal ideation is a risk factor for
suicidal behavior, but its assessment has to rely on imprecise and
subjective measures, hampered by patients' reluctance to report
suicidal thoughts.2,3 While many clinical variables are correlated
with suicidality, they are insufﬁcient to identify risk in individual
patients.3,4 Objectively measured biomarkers could contribute to
better risk prediction and clinical care.
A recent study by Le-Niculescu et al.5 investigated biomarkers
for suicidal ideation in a live discovery sample of patients with
bipolar disorder (n= 9). A Convergent Functional Genomics
approach was used to prioritize genes which were differentially
expressed between a high versus low suicidality state, on the basis
of ﬁndings from postmortem brain gene expression studies of
suicide victims, as well as genetic linkage or association studies on
suicide. The top biomarkers were tested for differential expression
in a validation sample of suicide victims (n= 9) and for ability to
predict past and future hospitalizations for suicidality in two
follow-up cohorts with either bipolar disorder (n= 42) or psychosis
(n= 46). It was reported that changes in the expression of four
genes: spermidine/spermine N1-acetytransferase 1 (SAT1), phos-
phatase and tensin homolog (PTEN), mitogen-activated protein
kinase kinase kinase 3 (MAP3K3) and myristoylated alanine-rich
protein kinase C substrate (MARCKS) in the blood, could be used as
biomarkers of a high versus low suicidal state and could predict
hospitalizations for suicidality.5
Biomarker research, in general, is plagued with overestimation
of results in discovery studies with subsequent lack of replication,
and ﬁndings which usually have limited predictive ability.6,7
Currently, in psychiatry there are no biomarkers of clinical utility.7
In suicidality biomarker research, the study of genetic, immuno-
logical and neuroendocrine biomarkers has generated inconsis-
tent results, with little or no replication of initial ﬁndings.8
Replication in large independent samples by independent
research groups is essential to validate the results of biomarker
discovery studies. Here, we investigate the expression of the
proposed biomarkers SAT1, PTEN, MAP3K3 and MARCKS, in patients




The Genome-Based Therapeutic Drugs for Depression Study (GENDEP) is a
prospective pharmacogenetic study of patients with major depressive
disorder (n= 868) receiving 12-week antidepressant treatment.9 Partici-
pants were recruited from nine European centers and diagnosed with
major depressive disorder using the Schedules for Clinical Assessment in
Neuropsychiatry Interview (SCAN), according to the International Classiﬁ-
cation of Diseases 10th edition (ICD-10) or Diagnostic and Statistical
Manual of Mental Disorders 4th edition (DSM-IV).10–12 SCAN interviews
were conducted by psychologists or psychiatrists trained at World Health
Organisation Training and Research Centres. Exclusion criteria were
psychotic disorder with mood incongruent psychotic symptoms or bipolar
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disorder.9 Patients received a protocol-guided treatment with either
escitalopram—a selective serotonin reuptake inhibiter or nortriptyline—a
tricylic antidepressant.9 All participants in the GENDEP study were of
Caucasian European parentage.9
Patients gave written informed consent and ethical approval was
obtained from the local ethics committee at each center of recruitment.
The GENDEP trial is registered at EudraCT (no. 2004-001723-38) and ISRCTN
(no. 03693000).
Gene expression measurement
Blood was collected in PAXgene tubes (PreAnalytiX, Hombrechtikon,
Switzerland) at both week 0 and week 8 for 136 participants and frozen at
− 80 °C.13 PAXgene tubes were allowed to thaw for 12 h at room
temperature and mRNA was isolated from whole blood using the Qiagen
PAXgene Blood miRNA Kit (PreAnalytiX) following the manufacturer's
protocol.14 Genome-wide expression analysis was performed in four
batches on Illumina Human HT-12 v4 BeadChip microarrays (Illumina, San
Diego, CA, USA).
Quality control was performed using R 3.0.2. Gene expression values
were log transformed. In the analysis of outliers of gene expression, 13
patients were excluded because the expression in one of their paired
samples fell below 2 s.d. from the mean inter-array correlation. Additional
ﬁltering using sex-incongruent expression of probes within the XIST gene
removed a further two samples. Detection score P-values were used for
probe ﬁltering (Po0.1 in at least one sample), and probes displaying little
variation were also removed (where s.d. was in the lowest quartile
o0.12030). After ﬁltering, a total of 121 paired samples remained, with
29 765 probes. Data were normalized using quantile normalization, and
ComBat was used to control for batch effects.15 Probes of interest were
ILMN_1753342 (SAT1), ILMN_1701134 (PTEN), ILMN_1779010 and
ILMN_2296697 (mean expression level was used for MAP3K3) and
ILMN_1807042 (MARCKS).
Phenotype deﬁnition
Suicidal ideation was assessed weekly using items from the clinician-rated
17-item Hamilton Rating Scale for Depression, the Montgomery-Åsberg
Depression Rating Scale and the self-report Beck Depression
Inventory.16–18 Response options of these items are shown in Table 1.
The three items were combined into a composite suicidal ideation score
using item response theory.19 Signiﬁcant suicidal ideation at baseline was
deﬁned as at least 1 s.d. above the minimum score on the composite
scale.19 As previously described, treatment-worsening suicidal ideation was
considered an increase of at least 0.5 s.d., above their original score in a
patient with signiﬁcant suicidal ideation at baseline. Treatment-emergent
suicidal ideation was deﬁned as surpassing the threshold for suicidal
ideation and an increase of 0.5 s.d. above their original score, in patients
without signiﬁcant suicidal ideation at baseline.19 Individuals with either
treatment-emergent suicidal ideation or treatment-worsening suicidal
ideation at any point during the 12-week study were used as cases of
treatment-related suicidal ideation (RxSI+; n= 20). The worst week for
suicidal ideation emerging or increasing was week 5 and none of the
patients became suicidal or worsened after week 8.19 This deﬁnition
corresponds to an increase of one unit on the Hamilton Rating Scale for
Depression, as used by Le-Niculescu et al.5 Individuals with scores under
the threshold for suicidal ideation at each week and who did not show an
increase of 40.5 s.d. above their baseline score were used as controls
(non-SI; n=37).19 The remaining individuals with paired transcriptomics
data were excluded as they did not meet this case or control deﬁnition
(n=64).
Statistical analysis
Two analyses were used to test for change in expression in RxSI+ patients
and control (non-SI) patients. In a within-subjects design, a paired sample
t-test was used to compare gene expression at week 0 and week 8 within
the case and control groups, following the protocol used by Le-Niculescu
et al.5 In a between-subjects design, the relationship between case (RxSI+)
and control (non-SI) status and change in gene expression (week 8−week
0) was assessed using logistic regression, co-varying for age, sex, drug
treatment, gene expression at week 0 and also center of recruitment, to
capture any remaining variation in population structure.
Power calculation
This study had 98% power to detect a standardized difference in
expression of 1.14 between cases with suicidal ideation versus non-
suicidal controls, the largest reported difference in gene expression in the
original paper.5 There was also good power to detect smaller changes in
gene expression between cases and controls, with 80% power to detect an
effect size of 0.79 and 60% power to detect an effect size of 0.62.
RESULTS
Individuals with suicidal ideation were signiﬁcantly older than
controls (P= 0.02), whereas there was no difference in sex or drug
treatment between suicidal ideation cases and controls (Table 2).
Within-subjects comparison
No signiﬁcant difference in expression between week 0 and week
8 was detected for any gene, within either the RxSI+ cases or the
non-SI controls (Table 3). Further, initiation of antidepressant
treatment had no effect on the expression of these four genes in
RxSI+ cases and non-SI controls (Figure 1).
Between-subjects comparison
The change in gene expression from week 0 to week 8 was
compared between RxSI+ cases and non-SI controls using logistic
regression, co-varying for age, sex, drug treatment, gene




1 Feels life is not worth living
2 Wishes he/she were dead, or any thought of
possible death to self
3 Suicide ideas or half-hearted attempt
4 Attempts suicide
MADRS 0–1 Enjoys life or take it as it comes
2–3 Weary of life. Only ﬂeeting suicidal thoughts
4–5 Probably better off dead. Suicidal thoughts are
common, and suicide is considered as a possible
solution, but without speciﬁc plans or intentions
6 Explicit plans for suicide when there is an
opportunity. Active preparation of suicide
BDI 0 Absent
1 Thought of killing myself
2 I would like to kill myself
3 I would like to kill myself if I had a chance
Abbreviations: BDI, Beck Depression Inventory; HRSD, Hamilton Rating Scale
for Depression; MADRS, Montgomery–Åsberg Depression Rating Scale.








Male 5 (25.0%) 10 (27.0%)
Female 15 (75.0%) 27 (72.9%)
Mean age (years) (s.d.) 48.7 (13.3) 39.8 (12.8) 0.020
Drug 0.779
Escitalopram 12 (60.0%) 25 (67.6%)
Nortriptyline 8 (40.0%) 12 (32.4%)
Abbreviations: non-SI, controls without suicidal ideation; RxSI+, treatment-
related suicidal ideation. P-value was determined using a chi-squared test,
with the exception of age, where a nonparametric Mann–Whitney U-test
was used.
Blood biomarkers for suicidality
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expression at week 0 and center of recruitment. There was no
signiﬁcant difference in the change in gene expression between
cases versus controls for any gene tested (Table 4).
DISCUSSION
Suicidal ideation is difﬁcult to predict and assess, so the use of
objectively measured biomarkers would be advantageous. Con-
trary to the ﬁndings of Le-Niculescu et al.,5 our analysis of the
blood expression levels of SAT1, PTEN, MAP3K3 and MARCKS genes
showed no difference between depressed patients with suicidal
ideation versus those without.
Although the sample size in this study is small (n= 20 cases and
n= 37 controls), it is larger than the primary analysis, which used a
discovery cohort of nine patients and three small and hetero-
geneous replication samples.5 The original analysis was conducted
in an all-male sample and so results may lack generalizability. The
GENDEP sample is mixed and thus more representative of the
natural epidemiology of suicidality in major depressive
disorder.20,21 The index of suicidal ideation used here incorporates
three clinical scales (including that used in the original report) with
a mixture of patient self-report and clinician ratings. The within-
subjects analysis used to compare gene expression at week 0 and
week 8 is a powerful design as it can remove the possible
inﬂuence of genetics, as well as other patient-speciﬁc factors, on
suicidal ideation during the study period.22,23 Furthermore, this
study has 98% power to detect the effect sizes previously
reported.
Expression of SAT1 in our study was slightly lower in RxSI+ cases
than in non-SI controls, though not signiﬁcantly different. This is in
the opposite direction to the ﬁndings reported by Le-Niculescu
et al.,5 though in support of previous studies, which demonstrated
decreased levels of SAT1 mRNA in several brain regions of suicide
victims.24–28
Assessment of blood biomarkers may not be a reliable
representation of brain function but it does provide easilyTable 3. Difference in gene expression between week 0 and week 8
Gene RxSI+ cases Non-SI controls
Mean difference in
expression (s.d.)
P-value Mean difference in
expression (s.d.)
P-value
SAT1 − 0.072 (0.311) 0.312 0.018 (0.196) 0.570
PTEN − 0.037 (0.361) 0.648 − 0.014 (0.365) 0.817
MAP3K3 0.023 (0.194) 0.591 0.009 (0.269) 0.834
MARCKS − 0.148 (0.353) 0.075 − 0.003 (0.306) 0.950
Abbreviations: non-SI, controls without suicidal ideation; RxSI+, treatment-
related suicidal ideation. P-values were calculated using a paired t-test.
Figure 1. (a–d) Change in gene expression (week 8−week 0) in RxSI+ case and non-SI control groups for (a) SAT1, (b) PTEN, (c) MAP3K3 and
(d) MARCKS. Error bars represent 1 s.e.m. change in expression. RxSI+, treatment-related suicidal ideation; non-SI, controls without suicidal
ideation.
Table 4. Difference in change in gene expression between week 0
and week 8 in cases versus controls
Gene Regression coefﬁcient Standard error P-value
SAT1 − 2.067 1.707 0.226
PTEN − 0.737 1.265 0.560
MAP3K3 − 2.326 2.541 0.360
MARCKS −2.240 1.401 0.110
P-values were calculated using a logistic regression controlling for age, sex,
drug, expression at week 0 and center of recruitment.
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obtainable measures which could be useful in patient monitoring.
Suicidal ideation is a complex phenotype and its etiology is poorly
understood. It is likely that larger sample sizes and a model
including multiple clinical and biological risk factors, will be
required to form a robust predictor with clinical utility.
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a	 state-of-science	 review	 on	 the	 challenges	 that	 have	 faced	 depression	 genetics	 and	 the	
strategies	that	have	been	used	by	recent	successful	GWAS,	such	as	targeted	efforts	to	reduce	
heterogeneity	 in	depression	and	 innovative	approaches	 to	 increase	 sample	 size	 (Mullins	and	
Lewis,	2017).		
	







To	 investigate	 how	 psychiatric	 disorders	 persist,	 despite	 the	 reduced	 fecundity	 of	 affected	
individuals,	Chapter	4	examined	the	selection	pressures	on	common	and	rare	genetic	variants	










samples.	This	 is	 the	 first	 consortium-based	GWAS	on	 suicide	attempt	and	makes	progress	 in	
amassing	the	large	sample	sizes	required	for	robust	genetic	studies	on	this	serious	condition.	
Finally,	 in	Chapter	6,	an	 independent	test	of	blood	mRNA	levels	of	SAT1,	PTEN,	MAP3K3	and	







After	 years	 of	 lagging	 behind	 other	 psychiatric	 disorders,	 GWAS	 on	 depression	 are	 now	
beginning	to	 identify	the	genetic	variants	 involved	(Mullins	and	Lewis,	2017).	The	CONVERGE	









combining	 clinically	ascertained	MDD	samples,	 cases	 from	population	biobanks	and	 the	 self-
report	 data	 from	 23andMe	 (Major	 Depressive	 Disorder	 Working	 Group	 of	 the	 Psychiatric	
Genomics	Consortium	et	al.,	2017).	This	study	has	made	rapid	progress	in	increasing	sample	size,	
achievable	since	depression	 is	a	common	disorder,	and	MDD	now	has	 the	 largest	number	of	
cases	of	any	disorder	investigated	within	the	PGC	(Sullivan	et	al.,	2017).	
	







that	 future	 studies	 should	 be	 able	 to	 elucidate	 the	 bulk	 of	 the	 common	 variant	 genetic	
architecture	of	MDD	using	a	cost-effective	shortcut	-	large	studies	of	genotyped	individuals	who	
complete	brief	lifetime	MDD	screening	as	opposed	to	lengthy	and	expensive	clinical	interviews.	
This	 strategy	 can	 be	 used	 to	 identify	 genetic	 associations	which	 can	 then	 be	 followed	up	 in	














































with	childhood	 trauma	 increased	 risk	 for	depression	 (Peyrot	et	al.,	2014).	To	 further	explore	
these	 findings,	 the	PGC	subsequently	conducted	a	meta-analysis	of	 interaction	results	across	
Radiant	UK,	NESDA	and	seven	other	MDD	cohorts	with	childhood	trauma	information	available,	
again	using	a	more	powerful	MDD	PRS	(Peyrot	et	al.,	2017).	This	analysis	showed	no	evidence	


































also	 been	 conducted	 (Keers	 et	 al.,	 2016).	 This	 novel	 design	 included	 one	 of	 each	 pair	 of	
monozygotic	 twins,	 with	 the	 outcome	 measure	 being	 the	 twins’	 intra-pair	 difference	 in	
emotional	problems	(Keers	et	al.,	2016).	The	basic	principle	 is	that	the	variability	 in	outcome	
between	a	monozygotic	twin	pair	must	be	the	result	of	non-shared	environmental	effects	and	








is	 often	 neglected	 in	 psychiatric	 research	 and	 uncovering	 protective	 interactions	 could	








To	 investigate	 how	 psychiatric	 disorders	 persist,	 despite	 the	 reduced	 fecundity	 of	 affected	
individuals,	Chapter	4	examined	the	selection	pressures	on	common	and	rare	genetic	variants	
for	 psychiatric	 disorders	 in	 unaffected	 individuals	 in	 the	 Icelandic	 population	 (Mullins	 et	 al.,	
2017).	PRS	 for	ADHD	were	associated	with	having	more	children,	while	PRS	 for	autism	were	
associated	 with	 having	 fewer	 children,	 indicating	 that	 common	 genetic	 variants	 that	 are	
thousands	of	years	old	are	currently	subject	to	weak	selection	pressure.	It	is	perhaps	surprising	
that	these	two	PRS	were	associated	with	fecundity,	given	that	they	have	lower	predictive	power	
than	 others	 tested,	 for	 example	 the	 PRS	 for	 schizophrenia	 and	 bipolar	 disorder.	 However,	
individuals	who	carry	a	high	burden	of	risk	alleles	for	these	disorders	may	display	intermediate	
phenotypes	which	 could	 have	 effects	 on	 fecundity	 or	 ability	 to	 find	 a	 partner;	 for	 example,	
genetic	liability	for	autism	has	been	associated	with	autistic-like	traits	in	the	general	population	














and	 as	 larger	 discovery	 GWAS	 are	 conducted,	 other	 associations	 with	 fecundity	 may	 be	
uncovered.	 While	 this	 study	 found	 no	 evidence	 that	 schizophrenia	 risk	 alleles	 are	 under	
selection,	 a	 recent	 paper	 proposed	 a	 mechanism	 by	 which	 these	 variants	 are	 maintained	
(Pardiñas	 et	 al.,	 2016).	 Using	 data	 from	 the	 latest	 GWAS,	 common	 genetic	 variants	 for	














Natural	 selection	 shapes	 the	 genetic	 landscape	 of	 heritable	 traits	 and	 studying	 this	 is	 now	
possible	using	population	genetic	biobanks,	large-scale	case-control	samples	and	bioinformatics	
approaches	 for	 annotation.	 Investigating	 the	 selection	 pressures	 on	 genetic	 variants	 can	
illuminate	 the	 genetic	 architecture	 of	 psychiatric	 disorders	 and	 guide	 future	 gene-mapping	




One	 final	 important	 finding	 from	 Chapter	 4	 is	 in	 relation	 to	 parental	 age.	 The	 link	 between	
advanced	paternal	age	and	risk	of	psychiatric	disorders	has	widely	been	assumed	to	be	due	to	
de	 novo	 mutations	 in	 the	 spermatogonial	 stem	 cells	 of	 older	 males	 (Kong	 et	 al.,	 2012).	
Population	genetic	modelling	has	calculated	that	these	mutations	are	unlikely	to	explain	much	
of	the	paternal	age	effect,	but	a	weak	correlation	between	age	at	first	child	and	genetic	liability	
to	psychiatric	 illness	could	account	 for	 the	observed	 incidence	of	psychiatric	disorders	 in	 the	














Psychiatric	 Genomics	 Consortium.	 The	 study	 found	 three	 genome-wide	 significant	 loci	
associated	with	 suicide	 attempt	 in	MDD	 or	 bipolar	 disorder	 implicating	 the	ARL5B	 gene,	 an	
intergenic	region	between	IWS1	and	MYO7B	and	a	non-coding	RNA	LOC105374524.	Replication	
of	 these	 associations	 in	 independent	 samples	 is	 essential	 and	 is	 part	 of	 a	 planned	 future	





cohorts.	The	number	of	 cases	 is	 five-fold	 larger	 than	any	previous	GWAS	on	suicide	attempt	
(Sokolowski	et	al.,	2014).	However,	unsurprisingly,	polygenic	risk	scoring	and	ℎ"#$% 	calculations	
revealed	that	a	further	increase	in	sample	size	will	be	necessary	to	fully	interrogate	the	common	
genetic	 architecture	 of	 this	 polygenic	 trait.	 In	 this	 GWAS,	 most	 support	 was	 seen	 for	 the	
chromosome	4	locus	 in	LOC105374524	and	the	association	was	specific	to	suicide	attempt	in	




of	 MDD,	 heterogeneity	 has	 profound	 implications	 for	 statistical	 power,	 so	 resolving	 the	
relationship	 between	 suicide	 attempt	 in	 different	 disorders	 is	 important	 for	 strategically	
planning	 future	 GWAS.	 An	 additional	 potential	 caveat	 is	 that	 one	 twin	 study	 estimated	 the	
heritability	of	suicide	attempt	after	adjusting	for	psychiatric	disorders	to	be	17%	(Fu	et	al.,	2002).	
This	 lower	 heritability	 would	 also	 reduce	 power,	 meaning	 that	 larger	 sample	 sizes	 will	 be	
required	to	detect	genetic	associations.		
	
Prediction	 and	 prevention	 is	 imperative	 in	 reducing	 the	 burden	 of	 suicide.	 However,	 it	 is	
particularly	challenging	for	this	phenotype	because	clinicians	often	must	rely	on	voluntary	self-
report	 from	 patients	 who	 are	 reluctant	 to	 disclose	 this	 information.	 There	 are	 currently	 no	
robust	methods	of	assessing	suicide	risk	and	meta-analysis	of	50	years	of	research	on	known	risk	
factors	such	as	psychiatric	illness,	demographics,	family	history	and	prior	suicidal	thoughts	and	







et	al.,	2014a).	This	paper	makes	a	valuable	contribution	 to	 the	scientific	 literature,	given	the	









health	 records	 and	 in	 the	 future	 combining	 biomarkers	with	 other	 variables	may	 be	 a	 good	
strategy	to	improve	their	predictive	capacity	(Smoller,	2017).	For	now,	biomarker	research	can	











for	 GxE	 research,	with	 uniform	 or	 at	 least	 highly	 correlated	 environmental	measures	 across	
cohorts.	Naturally,	an	alternate	approach	is	to	conduct	a	single	large	homogenous	GxE	study.	
The	UK	 Biobank	 is	 a	 prospective	 cohort	 study	 of	 ~500,000	 individuals	with	 genetic	 and	 rich	




gene-environment	 interplay	 in	 depression	 (Tyrrell	 et	 al.,	 2017).	 Given	 the	 high	 genetic	
correlation	 observed	 between	 MDD	 and	 depressive	 symptoms,	 combining	 clinical	 and	
population	level	data	in	GxE	research	may	also	bring	novel	insights.		
	




public	 health	 and	 searches	 for	de	 novo	mutations.	 In	 the	 future,	 increased	 coverage	 of	 the	
genome	through	whole	genome	sequencing	will	provide	more	insights	into	genetic	architecture,	




sample	 size.	 In	 the	 first	 instance,	 this	 could	 be	 feasible	 within	 the	 PGC,	 by	 extending	 this	
collaboration	 to	 working	 groups	 on	 other	 disorders	 where	 cohorts	 may	 have	 information	













MDD	 is	 a	 heterogeneous	 disorder	 in	 symptoms,	 genetics	 and	 environmental	 risk	 factors.	
Genome-wide	association	studies	have	made	progress	at	last	in	identifying	the	genetic	variants	
involved	 and	 increases	 in	 sample	 size	 will	 lead	 to	 more	 discoveries.	 The	 availability	 of	
phenotypic,	genetic	and	environmental	data	provides	abundant	opportunities	to	leverage	the	
heterogeneity	 of	 depression	 in	 the	 quest	 to	 understand	 its	 complex	 aetiology.	 This	 thesis	
contributes	 to	 the	 scientific	 literature	 by	 dissecting	 the	 interplay	 between	 genetics	 and	
environmental	risk	factors,	the	selection	on	risk	alleles	at	a	population	level	and	the	genetic	basis	
of	suicide	attempt,	a	serious	symptom	of	MDD.	Genetic	studies	of	major	depressive	disorder	
provide	promise	for	translating	biology	into	new	clinical	tools	for	the	treatment	and	prevention	
of	this	debilitating	disorder.	
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